

# Morgan Stanley

## First Addendum to the Base Listing Document dated 17 March 2021 relating to Non-collateralised Structured Products

### Issuer

## Morgan Stanley Asia Products Limited

*(Incorporated in the Cayman Islands with limited liability)*

### Guarantor

## Morgan Stanley

*(Incorporated in the State of Delaware, United States of America)*

### Manager

## Morgan Stanley Asia Limited

*(Incorporated in Hong Kong)*

---

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.

This document, for which we and the Guarantor accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (“**Stock Exchange’s Listing Rules**”) for the purpose of giving information with regard to the Issuer, the Guarantor and the warrants, callable bull/bear contracts (“**CBBCs**”) and any other structured products (together, “**our structured products**”) referred to in this document. The Issuer and the Guarantor, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this document and our base listing document dated 17 March 2021 (“**Base Listing Document**”) is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or these documents, when read together, misleading. This document should be read together with the Base Listing Document.

We, the Issuer of our structured products, are publishing this document in order to obtain a listing on the Stock Exchange of our structured products.

**The structured products are complex products. You should exercise caution in relation to them. Investors are warned that the price of the structured products may fall in value as rapidly as it may rise and holders may sustain a total loss of their investment. Prospective purchasers should therefore ensure that they understand the nature of the structured products and carefully study the risk factors set out in the Base Listing Document and, where necessary, seek professional advice, before they invest in the structured products.**

**The structured products constitute general unsecured contractual obligations of the Issuer and of no other person and the guarantee constitutes the general unsecured contractual obligations of the Guarantor and of no other person and will rank equally among themselves and with all our and the Guarantor’s other unsecured obligations (save for those obligations preferred by law) upon liquidation. If you purchase the structured products, you are relying upon the creditworthiness of the Issuer and the Guarantor, and have no rights under the structured products against (a) the company which has issued the underlying securities, (b) the trustee or the manager of the underlying trust, or (c) the index sponsor of any underlying index or any other person. If the Issuer becomes insolvent or default on its obligations under the structured products or the Guarantor becomes insolvent or defaults on its obligations under the guarantee, you may not be able to recover all or even part of the amount due under the structured products (if any).**

The structured products are not bank deposits or protected deposits for the purposes of the Deposit Protection Scheme in Hong Kong and are not insured or guaranteed by the United States Federal Deposit Insurance Corporation (“**FDIC**”), or any other governmental agency. The structured products are guaranteed by Morgan Stanley and the guarantee will rank *pari passu* with all other direct, unconditional, unsecured and unsubordinated indebtedness of Morgan Stanley.

The distribution of this document, the Base Listing Document, the relevant launch announcement and supplemental listing document, any addendum and the offering, sale and delivery of structured products in certain jurisdictions may be restricted by law. You are required to inform yourselves about and to observe such restrictions. Please read Annex 3 “Purchase and Sale” in the Base Listing Document. The structured products have not been approved or disapproved by the SEC or any state securities commission in the United States or regulatory authority, nor has the SEC or any state securities commission or any regulatory authority passed upon the accuracy or the adequacy of this document. Any representation to the contrary is a criminal offence. **The structured products and the guarantee have not been and will not be registered under the United States Securities Act of 1933, as amended (“Securities Act”), and the structured products may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons (as defined in Regulation S under the Securities Act).**

Dated 30 April 2021

## **IMPORTANT**

If you are in doubt as to the contents of this document, you should obtain independent professional advice.

This document contains the Issuer's financial statements as of 31 December 2020 and for the year ended 31 December 2020. You should read this document, the Base Listing Document and the relevant launch announcement and supplemental listing document published by us in relation to the particular series of structured products you are considering for investment to understand our structured products before deciding whether to buy our structured products.

Copies of this document, the Base Listing Document and the relevant launch announcement and supplemental listing document (together with a Chinese translation of each of these documents) and other documents listed under the section "Where can I read copies of the Issuer's and Guarantor's documentation?" in the Base Listing Document may be inspected at the offices of Morgan Stanley Asia Limited at Level 46, International Commerce Centre, 1 Austin Road West, Kowloon, Hong Kong.

本文件，基本上市文件及相關發行公佈及補充上市文件（及以上各份文件的英文本）連同基本上市文件的「本人從何處可查閱發行人及擔保人的文件副本？」一節所列的其他文件，可於摩根士丹利亞洲有限公司的辦事處（地址為香港九龍柯士甸道西1號環球貿易廣場46樓）查閱。

We do not give you investment advice; you must decide for yourself, after reading the listing documents for the relevant structured products and, if necessary, seeking professional advice, whether our structured products meet your investment needs.

Our Guarantor's long term credit ratings (as of the day immediately preceding the date of this document) are: A1 (Stable) by Moody's Investors Service, Inc. and BBB+ (Stable) by S&P Global Ratings.

Save as disclosed in the Base Listing Document and this document, the Issuer and our Guarantor are not aware, to the best of our and our Guarantor's knowledge and belief, of any litigation or claims of material importance pending or threatened against us or our Guarantor.

Save as disclosed in Annex 6 to the Base Listing Document and this document, there has been no material adverse change in the Issuer's and our Guarantor's financial or trading position since the date of the most recently published audited consolidated financial statements of the Issuer and our Guarantor that would have a material adverse effect on the Issuer's and our Guarantor's ability to perform their respective obligations in respect of the structured products.

## **CONTENTS**

<b>ISSUER'S FINANCIAL STATEMENTS AS OF 31 DECEMBER 2020 AND FOR THE YEAR ENDED 31 DECEMBER 2020</b> .....	<b>2</b>
---------------------------------------------------------------------------------------------------------------	----------

## **ISSUER'S FINANCIAL STATEMENTS AS OF 31 DECEMBER 2020 AND FOR THE YEAR ENDED 31 DECEMBER 2020**

This information set out in the following pages is the Issuer's financial statements as of 31 December 2020 and for the year ended 31 December 2020.

References to page numbers on the following pages are to the pages in such financial statements and not to the pages in this document.

As at the date of this document, the Issuer's auditor, Deloitte & Touche LLP, has given and has not withdrawn its written consent to the inclusion of its report on the Issuer's financial statements as of 31 December 2020 and for the year ended 31 December 2020 dated 14 April 2021 in this document and/or references to its name in the listing documents, in the form and context in which it is included. Its report was not prepared for incorporation into this document. The Issuer's auditor does not have any shareholding in us or the Guarantor or any of the Guarantor's subsidiaries nor does it have the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for our securities or securities of the Guarantor or any of the Guarantor's subsidiaries.

Please refer to (i) our base listing document dated 17 March 2020 ("**2020 BLD**") for the Guarantor's consolidated financial statements as of 31 December 2019 and 2018 and for each of the three years in the period ended 31 December 2019 and the report of the auditor, Deloitte & Touche LLP, on such consolidated financial statements and (ii) the first addendum to the 2020 BLD dated 29 April 2020 for the Issuer's financial statements as of 31 December 2019 and 2018 and for each of the two years in the period ended 31 December 2019 and the report of the auditor, Deloitte LLP, on such financial statements.

**MORGAN STANLEY ASIA PRODUCTS LIMITED**

**Report and financial statements**

**31 December 2020**

# **MORGAN STANLEY ASIA PRODUCTS LIMITED**

## **REPORT AND FINANCIAL STATEMENTS**

**Year ended 31 December 2020**

<b>CONTENTS</b>	<b>PAGE</b>
Directors' report	1
Directors' responsibility statement	7
Independent auditors' report	8
Statement of comprehensive income	10
Statement of changes in equity	11
Statement of financial position	12
Statement of cash flows	13
Notes to the financial statements	14

# **MORGAN STANLEY ASIA PRODUCTS LIMITED**

## **DIRECTORS' REPORT**

The Directors present their report, responsibility statement and financial statements (which comprise the statement of comprehensive income, statement of changes in equity, statement of financial position, statement of cash flows and the related notes, 1 to 23) of Morgan Stanley Asia Products Limited (the "Company") for the year ended 31 December 2020.

### **RESULTS AND DIVIDENDS**

The result for the year, after tax, was US\$nil (2019: US\$nil).

During the year, no dividends were paid or proposed (2019: US\$nil).

### **PRINCIPAL ACTIVITY**

The principal activity of the Company is the issuance of financial instruments, with a primary focus on the Asia markets, and the hedging of the obligations arising pursuant to such issuances.

The Company's ultimate parent undertaking and controlling entity is Morgan Stanley, which, together with the Company and Morgan Stanley's other subsidiary undertakings, form the "Morgan Stanley Group".

There have not been any significant changes in the Company's principal activity in the year under review and no significant change in the Company's principal activity is expected.

### **BUSINESS REVIEW**

#### **Global market and economic conditions**

The Coronavirus ("COVID-19") pandemic severely damaged economic activities across both developed and emerging markets. Gross domestic product ("GDP") fell sharply, at an unprecedented rate in 2Q20, but also rebounded strongly in 3Q20 as economies began to reopen. On an annual average basis, the global economy shrank by 3.2% last year, with the developed markets' economy contracting by 5.2% and the emerging markets' economy declining by 1.7%. In 2021, global growth is expected to bounce back sharply to 6.4%, with a synchronous recovery taking hold across both developed and emerging markets. A global surge in demand from March/ April onwards will lift the global economy back onto its pre-covid path (i.e. where GDP would have been if the Covid-19 shock had not occurred) in 2Q21. In response to the sharp deterioration of economic activities in the first half of 2020, global policy makers swiftly implemented massive monetary and fiscal policy easing measures to provide support to households and businesses. In the United States ("US"), the Federal Reserve cut the federal funds rate to the zero lower bound in March and expanded its balance sheet by US\$3.2 trillion during 2020, equivalent to 15.3% of the annual GDP. The US government also introduced significant spending packages, including the US\$2.2 trillion CARES Act passed in March 2020 and another US\$900 billion relief bill passed in December, bringing its fiscal deficit to 14.9% of annual GDP, the highest since 1946. In the euro area, the European Central Bank expanded its balance sheet by EUR2.3 trillion as of the end of December 2020 or 20.5% of the region's 2020 annual GDP, and we estimate that its fiscal deficit reached 9.5% of GDP. In addition, in July 2020, the European Commission agreed to establish the European Recovery Fund worth EUR750 billion, backed by joint issuance, to provide EUR390 billion in grants and EUR360 billion in loans. Similarly, in the United Kingdom, the Bank of England lowered its Bank Rate to the lower bound in March, and we estimate that its balance sheet expanded by GBP340 billion, or 16.1% of GDP, last year. The various fiscal stimulus packages from the government also pushed the fiscal deficit to 12.9% of GDP.

In Japan, the Bank of Japan expanded its balance sheet by JPY129.5 trillion, or 24.1% of annual GDP in 2020, and the government of Japan passed three supplementary budgets throughout the year, pushing its fiscal deficit to an estimated multi-year high of 12.9% of GDP. In China, the People's Bank of China cut interest rates in the first half of the year, and the fiscal package announced at the National People's Congress in May brought the government's fiscal deficit to 15.4% of GDP. In India, the Reserve Bank of India cut its repo rate by 115 basis points ("bp") between March and May 2020, and provided multiple liquidity provision measures, including long-term repo operations and special liquidity facilities for bank and non-bank financial institutions. The government of India also announced multiple fiscal packages to provide support to affected businesses and individuals, widening its fiscal deficit to 12.5% of GDP in 2020 from 7.4% of GDP in 2019. In Hong Kong, the Hong Kong Monetary Authority lowered the base rate by

## **MORGAN STANLEY ASIA PRODUCTS LIMITED**

### **DIRECTORS' REPORT (CONTINUED)**

150bp between March and June 2020, and the government's fiscal deficit expanded to 8.5% of GDP in 2020 from 1.7% of GDP in 2019. Other major central banks, such as the Central Bank of Russia and the Central Bank of Brazil, also cut interest rates to multi-year lows, and governments in other economies similarly introduced measures to provide ample liquidity to businesses and relief to households.

#### **UK withdrawal from the European Union (“the EU”)**

On 31 January 2020, the United Kingdom (“UK”) withdrew from the EU under the terms of a withdrawal agreement between the UK and the EU. The withdrawal agreement provided for a transition period to the end of December 2020, during which time the UK would continue to apply EU law as if it were a member state, and UK firms' passporting rights to provide financial services in EU jurisdictions continued.

On 24 December 2020 the UK and the EU announced they had reached agreement on the terms of a trade and cooperation agreement to govern the future relationship between the parties. The agreement consists of three main pillars including: trade, citizens' security, and governance, covering a variety of arrangements in several areas. The agreement is provisionally applicable with effect from 1 January 2021 pending formal ratification by the EU.

With respect to financial services, although the UK chose to grant the EU equivalence in a number of key areas under European financial regulations, the EU only made certain more limited equivalence decisions, leaving decisions on equivalence and adequacy to be determined by each of the UK and EU unilaterally in due course. As a result, UK licensed entities, are unable to provide regulated services in a number of EU jurisdictions from the end of December 2020, absent regulatory relief or other measures implemented by individual countries.

While Morgan Stanley Group has restructured its European operations to ensure that it can continue to provide cross-border banking and investment and other services in EU member states, there continues to be uncertainty regarding the future regulatory landscape which could impact Morgan Stanley Group's European operations beyond those implemented or planned, as a result of which Morgan Stanley Group's results of operations and business prospects could be negatively affected.

#### **Overview of 2020**

The statement of comprehensive income for the year is set out on page 10. The result for the year was US\$nil which is consistent with the Company's function and the prior year. The Company hedges its issuances with bilateral over-the-counter (“OTC”) derivative contracts classified as trading financial assets or liabilities, loans designated at fair value through profit or loss (“FVPL”) and prepaid equity securities contracts. Net trading expense of US\$762,000 (2019: US\$133,000) represents net fair value movement on listed and bilateral OTC derivative contracts classified as trading financial assets or liabilities. Net income from other financial instruments held at fair value of US\$26,000 (2019: US\$11,000) represents net fair value movement on issued warrants, structured notes and their hedging financial instruments classified as prepaid equity securities contracts and loans respectively. All issued warrants, structured notes listed on Irish stock exchange and corresponding prepaid equity securities contracts and loans have been matured during the year and have a carrying value of US\$nil in the statement of financial position as on 31 December 2020. Issued listed derivative contracts have underlying securities predominantly in the Hong Kong market.

The statement of financial position for the Company is set out on page 12. The Company's financial position at the end of the year shows that the total assets and total liabilities were US\$62,195,000 and US\$62,145,000 respectively, a decrease of 79% from the prior year. The decrease during the year is primarily due to maturity of issued warrants and structured notes and their corresponding hedging instruments.

## **MORGAN STANLEY ASIA PRODUCTS LIMITED**

### **DIRECTORS' REPORT (CONTINUED)**

#### **Risk management**

Risk is an inherent part of both Morgan Stanley and the Company's business activity and is managed by the Company within the context of the broader Morgan Stanley Group. The Morgan Stanley Group seeks to identify, assess, monitor and manage each of the various types of risk involved in its business activities, in accordance with defined policies and procedures. The Company's own risk management policies and procedures are consistent with those of the Morgan Stanley Group. The risk management policy framework includes escalation to appropriate senior management of the Company.

Set out below is an overview of the Company's policies for the management of financial risk and other significant business risks. Note 18 to the financial statements provides more detailed quantitative disclosures as well as qualitative information on the Company's financial risk management.

During the year 2020, the Company redeemed warrants and structured notes valuing US\$251,983,000 (2019: US\$434,845,000) and issued new warrants of US\$nil (2019: US\$391,639,000). The redemptions were driven by retirement and maturity of the warrants and structured notes. However, the Company had sufficient financial assets in the form of prepaid equity securities contracts, redeeming at the same time to meet the redemption obligations of the issued warrants listed on Irish stock exchange. Further, all issuances of financial liabilities are guaranteed by Morgan Stanley.

The Company has also entered into a financial support agreement with its immediate parent, Morgan Stanley Asia Securities Products LLC ("MSASP") and with Morgan Stanley Hong Kong 1238 Limited ("MSHK 1238"), whereby MSASP and MSHK 1238 agree to provide financial support by way of funds injection in the form of equity capital or shareholders loan in the event the Company needs funds to fulfil its obligations and liabilities under its issuance programme.

#### *Market risk*

Market risk refers to the risk that a change in the level of one or more market prices, rates, spreads, indices, implied volatilities, correlations or other market factors, such as market liquidity, will result in losses for a position or portfolio. The Company is subject to market price risk exposure for its issuances, however, for each issuance, the Company enters into risk-mirroring contracts to fully hedge each type of market risk arising from its issuances. Accordingly, the Company has no net exposure to market risk.

The Morgan Stanley Group manages the market risk associated with its trading activities on a global basis, at both a trading division and an individual product level and includes consideration of market risk at the legal entity level.

Market risk management policies and procedures for the Company are consistent with those of the Morgan Stanley Group and include escalation to the appropriate senior management personnel.

It is the policy and objective of the Company not to be exposed to market risk on a net basis as a result of its issuance activities.

#### *Credit risk*

Credit risk refers to the risk of loss arising when a borrower, counterparty or issuer does not meet its financial obligations to the Company.

Credit risk exposure is managed on a global basis and in consideration of each significant legal entity within the Morgan Stanley Group. Credit risk management policies and procedures for the Company are consistent with those of the Morgan Stanley Group and include escalation to appropriate senior management personnel.

#### *Liquidity risk*

Liquidity risk refers to the risk that the Company will be unable to finance its operations due to a loss of access to the capital markets or difficulty in liquidating its assets. Liquidity risk also encompasses the Company's ability (or perceived ability) to meet its financial obligations without experiencing significant business disruption or reputational damage that may threaten its viability as a going concern.



## **MORGAN STANLEY ASIA PRODUCTS LIMITED**

### **DIRECTORS' REPORT (CONTINUED)**

The primary goal of the Morgan Stanley Group's liquidity risk management framework is to ensure that the Morgan Stanley Group, including the Company, have access to adequate funding across a wide range of market conditions and time horizons. The framework is designed to enable the Morgan Stanley Group to fulfil its financial obligations and support the execution of the Company's business strategies. The framework is further described in note 18.

The Company hedges all of its financial liabilities arising from issuance of listed derivative contracts, warrants and structured notes by entering into risk mirroring contracts with its immediate parent and other Morgan Stanley Group undertakings.

The maturity analysis provided in note 18 reflects the liquidity risk arising from the financial assets and the financial liabilities presented in a way that is consistent with how the liquidity risk on these financial assets and financial liabilities is managed by the Company. As at 31 December 2020, the Company has a payable of US\$49,844,000 (31 December 2019: US\$283,603,000) within one year from the date of the financial statements. As a result of the Company's hedging strategy, the Company has adequate financial assets to meet the settlement of this obligation. As at 31 December 2020, the Company has financial assets of US\$59,895,000 (2019: US\$289,168,000) expected to be maturing within a year from the date of the financial statements.

#### *Operational risk*

Operational risk refers to the risk of loss, or of damage to the Company's reputation, resulting from inadequate or failed processes from human factors or from external events (e.g. fraud, theft, legal and compliance risks, cyber-attacks or damage to physical assets). Operational risk relates to the following risk event categories as defined by Basel Capital Standards: internal fraud; external fraud; employment practices and workplace safety; clients, products and business practices; business disruption and system failure; damage to physical assets; and execution, delivery and process management. Legal, regulatory and compliance risk is discussed below under "Legal, regulatory and compliance risk".

The Company, through the Morgan Stanley Group, has established an operational risk framework to identify, measure, monitor and control risk. It includes escalation to the Company's Board of Directors and appropriate senior management personnel. The Morgan Stanley Group employs a variety of risk processes and mitigates to manage its operational risk exposures. These include a governance framework, a comprehensive risk management programme and insurance. Operational risks and associated risk exposures are assessed relative to the risk tolerance reviewed and confirmed by the Board and are prioritised accordingly. The breadth and variety of operational risk are such that the types of mitigating activities are wide-ranging. Examples of activities include continuous enhancement of defenses against cyberattacks; use of legal agreements and contracts to transfer and/or limit operational risk exposures; due diligence; implementation of enhanced policies and procedures; exception management processing controls; and segregation of duties.

The Operational Risk Department provides independent oversight of operational risk and assesses measures and monitors operational risk against tolerance. The Operational Risk Department works with the business divisions and control groups to help ensure a transparent, consistent and comprehensive framework for managing operational risk within each area and across the Morgan Stanley Group.

The Operational Risk Department scope includes oversight of the technology risk, cybersecurity risk, information security risk and data risk management programme (e.g. cybersecurity), fraud risk management and prevention programme and third party risk management (supplier and affiliate risk oversight and assessment) programme. Furthermore, the Operational Risk Department supports the collection and reporting of operational risk incidents and the execution of operational risk assessments; provides the infrastructure needed for risk measurement and risk management; and ensures ongoing validation and verification of the Morgan Stanley Group's advanced measurement approach for operational risk capital.

Business Continuity Management maintains programmes for business continuity management and technology disaster recovery that facilitate activities designed to mitigate risk to the Morgan Stanley Group during a business continuity event. A business continuity event is an interruption with potential impact to normal business activity of the Morgan Stanley Group's people, operations, technology, suppliers and/or

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### DIRECTORS' REPORT (CONTINUED)

facilities. The business continuity management programme's core functions are business continuity planning and crisis management. As part of business continuity planning, business divisions and control groups maintain business continuity plans identifying processes and strategies to continue business critical processes during a business continuity event. Crisis management is the process of identifying and managing the Morgan Stanley Group's operations during business continuity events. Disaster recovery plans supporting business continuity are in place for critical facilities and resources across the Morgan Stanley Group.

The Morgan Stanley Group maintains a programme that oversees our cyber and information security risks. Our cybersecurity and information security policies, procedures and technologies are designed to protect the Morgan Stanley Group's information asset against unauthorised disclosure, modification or misuse and are also designed to address regulatory requirements. These policies and procedures cover a broad range of areas, including: identification of internal and external threats, access control, data security, protective controls, detection of malicious or unauthorised activity, incident response, and recovery planning.

#### *Legal, regulatory and compliance risk*

Legal, regulatory and compliance risk includes the risk of legal or regulatory sanctions, material financial loss, including fines, penalties, judgements, damages and/ or settlements or loss to reputation which the Company may suffer as a result of a failure to comply with laws, regulations, rules, related self-regulatory organisation standards and codes of conduct applicable to the Company's business activities. This risk also includes contractual and commercial risk, such as the risk that a counterparty's performance obligations will be unenforceable. It also includes compliance with Anti-Money Laundering, anti-corruption and terrorist financing rules and regulations.

The Company, principally through the Morgan Stanley Group's Legal and Compliance Division, has established procedures based on legal and regulatory requirements on a worldwide basis that are designed to facilitate compliance with applicable statutory and regulatory requirements and to require that the Morgan Stanley Group's policies relating to business conduct, ethics and practices are followed globally.

#### *Culture, values and conduct of employees*

All employees of the Morgan Stanley Group are accountable for conducting themselves in accordance with the Morgan Stanley Group's core values *Putting Clients First, Doing the Right Thing, Leading with Exceptional Ideas, Commit to Diversity and Inclusion, and Giving Back*. The Morgan Stanley Group's core values drive a shared set of behaviours and attributes that help employees make decisions consistent with the expectations of the Morgan Stanley Group's clients, shareholders, regulators, Board of Directors and the public. The Morgan Stanley Group is committed to reinforcing and confirming adherence to the core values through our governance framework, tone from the top management oversight, risk management and controls, and a three lines of defence structure (business, control functions such as Risk management and Compliance, and Internal Audit). The Morgan Stanley Group's Board is responsible for overseeing the Morgan Stanley Group's practices and procedures relating to culture, values and conduct, as set forth in the Morgan Stanley Group's Corporate Governance Policies. The Morgan Stanley Group's Culture, Values and Conduct Committee is the senior management committee that oversees the Firm-wide culture, values and conduct program. A fundamental building block of this program is the Morgan Stanley Group's Code of Conduct (the "Code") which establishes standards for employee conduct that further reinforce the Morgan Stanley Group's commitment to integrity and ethical conduct. Every new hire and every employee annually must attest to their understanding of and adherence to the Code of Conduct.

The annual employee performance evaluation process includes an evaluation of employee conduct related to risk management practices and the Morgan Stanley Group's expectations. The Morgan Stanley Group also has several mutually reinforcing processes to identify employee conduct that may have an impact on employment status, current year compensation and/or prior year compensation. For example, the Global Incentive Compensation Discretion Policy sets forth standards for managers when making annual compensation decisions and specifically require managers to consider whether their employees effectively managed and/or supervised risk control practices during the performance year. Management committees from control functions periodically meet to discuss employees whose conduct does not meet the Morgan Stanley Group's standards. These results are incorporated in the employees' performance evaluation,

## **MORGAN STANLEY ASIA PRODUCTS LIMITED**

### **DIRECTORS' REPORT (CONTINUED)**

which links to compensation and promotion decisions. The Morgan Stanley Group's clawback and cancellation provisions, which permit recovery of deferred incentive compensation and cover a broad scope of employee conduct, including any act or omission (including with respect to direct supervisory responsibilities) that constitutes a breach of obligation to the Morgan Stanley Group or causes a restatement of the Morgan Stanley Group's financial results, constitutes a violation of the Morgan Stanley Group's global risk management principles, policies and standards, or causes a loss of revenue associated with a position on which the employee was paid and the employee operated outside of internal control policies.

#### **DIRECTORS**

The following Directors held office throughout the year and to the date of approval of this report (except where otherwise shown):

Adrian Priddis

Christopher Blackman (Resigned 3 March 2020)

Jason Yates (Resigned 18 March 2021)

Jack Clien (Appointed 18 March 2021)

Richard Smerin

Scott Honey

Young Lee

#### **EVENTS AFTER THE REPORTING DATE**

There have been no significant events since the reporting date.

#### **AUDITOR**

Deloitte & Touche LLP, New York, have expressed their willingness to continue in office as auditor of the Company and a resolution to re-appoint them will be proposed at the forthcoming annual general meeting.

Approved by the Board and signed on its behalf



Director

Date 14 APR 2021

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### DIRECTORS' RESPONSIBILITY STATEMENT

The Directors, the names of whom are set out above, confirm that to the best of their knowledge:

- (a) the financial statements, which have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, have been prepared in accordance with the applicable set of accounting standards and give a true and fair view of the assets, liabilities, financial position and result of the Company; and
- (b) the Directors' report includes a fair review of the development and performance of the business and position of the Company, together with a description of the principal risks and uncertainties that the Company faces.

Approved by the Board and signed on its behalf on



\_\_\_\_\_  
Director

Date: 14 APR 2021



**Deloitte & Touche LLP**  
30 Rockefeller Center  
New York, NY 10112  
USA

Tel: 1 212-436-2000  
Fax: 1 212-436-5000  
www.deloitte.com

## **INDEPENDENT AUDITORS' REPORT**

The Board of Directors of  
Morgan Stanley Asia Products Limited

We have audited the accompanying financial statements of Morgan Stanley Asia Products Limited (the "Company"), which comprise the statements of financial position as of December 31, 2020, and the related statements of comprehensive income, changes in equity and cash flows for the year then ended, and the related notes to the financial statements.

We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United States of America, together with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants, and we have fulfilled our other ethical responsibilities in accordance with these requirements, respectively.

### **Responsibilities of Management and Those Charged With Governance for the Financial Statements**

Management is responsible for the preparation and fair presentation of these financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless management either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

### **Auditors' Responsibility**

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the International Standards on Auditing. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement, whether due to fraud or error. Reasonable assurance is a high level of assurance but is not a guarantee that an audit will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. We design audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error because fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation, structure, and content of the financial statements, including disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

As part of an audit, we exercise professional judgment and maintain professional skepticism throughout the audit. We also conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies or material weaknesses in internal control that we identify during our audit.


We believe the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### **Opinion**

In our opinion, the accompanying financial statements referred to above present fairly, in all material respects, the financial position of Morgan Stanley Asia Products Limited as of December 31, 2020 and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards issued by the International Accounting Standards Board.

### **Predecessor Auditors' Opinion on 2019 Financial Statements**

The financial statements of the Company as of and for the year ended December 31, 2019, were audited by other auditors in accordance with International Standards on Auditing (UK) whose report, dated April 22, 2020, expressed an unmodified opinion on those statements.

A handwritten signature in black ink that reads "Deloitte & Touche LLP". The signature is written in a cursive, slightly stylized font.

April 14, 2021

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### STATEMENT OF COMPREHENSIVE INCOME Year ended 31 December 2020

	Note	2020 US\$'000	2019 US\$'000
Net trading expense	4	(762)	(133)
Net income from other financial instruments held at fair value	5	26	11
Other revenue	6	10,297	-
Total non-interest revenues/ (expenses)		<u>9,561</u>	<u>(122)</u>
Interest income	7	736	122
Net revenues		<u>10,297</u>	<u>-</u>
Other expense	8	(10,297)	-
<b>RESULT BEFORE INCOME TAX</b>		<u>-</u>	<u>-</u>
Income tax	9	-	-
<b>RESULT AND TOTAL COMPREHENSIVE INCOME FOR THE YEAR</b>		<u><u>-</u></u>	<u><u>-</u></u>

All results were derived from continuing operations.

The notes on pages 14 to 53 form an integral part of the financial statements.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### STATEMENT OF CHANGES IN EQUITY Year ended 31 December 2020

	Share capital US\$'000	Retained earnings US\$'000	Total equity US\$'000
Balance at 1 January 2019	50	-	50
Result and total comprehensive income for the year	-	-	-
<b>Balance at 31 December 2019</b>	<u>50</u>	<u>-</u>	<u>50</u>
Result and total comprehensive income for the year	-	-	-
<b>Balance at 31 December 2020</b>	<u>50</u>	<u>-</u>	<u>50</u>

The notes on pages 14 to 53 form an integral part of the financial statements.



**MORGAN STANLEY ASIA PRODUCTS LIMITED**

**STATEMENT OF FINANCIAL POSITION  
As at 31 December 2020**

	Note	2020 US\$'000	2019 US\$'000
<b>ASSETS</b>			
Cash		575	600
Trading financial assets	11	7,934	3,991
Loans	10	-	468
Prepaid equity securities contracts	10	-	281,353
Trade and other receivables	12	<u>53,686</u>	<u>11,559</u>
<b>TOTAL ASSETS</b>		<u><u>62,195</u></u>	<u><u>297,971</u></u>
<b>LIABILITIES AND EQUITY</b>			
<b>LIABILITIES</b>			
Trading financial liabilities	11	61,692	16,052
Issued warrants	10	-	281,353
Issued structured notes	10	-	467
Trade and other payables	13	<u>453</u>	<u>49</u>
<b>TOTAL LIABILITIES</b>		<u>62,145</u>	<u>297,921</u>
<b>EQUITY</b>			
Share capital	14	50	50
Retained earnings		<u>-</u>	<u>-</u>
<b>Equity attributable to owners of the Company</b>		<u>50</u>	<u>50</u>
<b>TOTAL EQUITY</b>		<u>50</u>	<u>50</u>
<b>TOTAL LIABILITIES AND EQUITY</b>		<u><u>62,195</u></u>	<u><u>297,971</u></u>

These financial statements were approved by the Board and authorised for issue on

**14 APR 2021** :

Signed on behalf of the Board

  
Director

The notes on pages 14 to 53 form an integral part of the financial statements.

**MORGAN STANLEY ASIA PRODUCTS LIMITED**

**STATEMENT OF CASH FLOWS**  
**Year ended 31 December 2020**

	Note	2020 US\$'000	2019 US\$'000
<b>NET CASH FLOWS FROM OPERATING ACTIVITIES</b>	15b	35,089	10,132
<b>INVESTING ACTIVITIES</b>			
Purchase of prepaid equity securities contracts		-	(391,639)
Purchase of OTC derivative contracts		(28)	(1)
Proceeds from sale and maturity of prepaid equity securities contracts		251,514	433,462
Proceeds from loan repayment by other Morgan Stanley Group Undertakings		490	1,364
Issuance of loan to other Morgan Stanley Group undertakings		(35,114)	(10,052)
Interest received		7	19
<b>NET CASH FLOWS FROM INVESTING ACTIVITIES</b>		<u>216,869</u>	<u>33,153</u>
<b>FINANCING ACTIVITIES</b>			
Issuance of warrants		-	391,639
Redemption of issued structured notes		(469)	(1,383)
Redemption of issued warrants		(251,514)	(433,462)
<b>NET CASH FLOWS USED IN FINANCING ACTIVITIES</b>	15c	<u>(251,983)</u>	<u>(43,206)</u>
<b>NET (DECREASE)/ INCREASE IN CASH AND CASH EQUIVALENTS</b>		<u>(25)</u>	<u>79</u>
<b>CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR</b>		<u>600</u>	<u>521</u>
<b>CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR</b>	15a	<u><u>575</u></u>	<u><u>600</u></u>

The notes on pages 14 to 53 form an integral part of the financial statements.

# MORGAN STANLEY ASIA PRODUCTS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

### 1. CORPORATE INFORMATION

Morgan Stanley Asia Products Limited (the “Company”) is an exempt company incorporated and domiciled in the Cayman Islands with limited liability, at the following registered address c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, South Church Street, George Town, Grand Cayman, KY1-1104, Cayman Islands.

The Company’s immediate parent undertaking is MSASP which is incorporated in the Cayman Islands.

The Company’s ultimate parent undertaking and controlling entity is Morgan Stanley which, together with the Company and Morgan Stanley’s other subsidiary undertakings, form the Morgan Stanley Group. Morgan Stanley is incorporated in the State of Delaware, the United States of America. Copies of its financial statements can be obtained from [www.morganstanley.com/investorrelations](http://www.morganstanley.com/investorrelations).

The Company is engaged in the issuance of financial instruments and the hedging of obligations pursuant to such issuances.

### 2. BASIS OF PREPARATION

#### Statement of compliance

The Company has prepared its annual financial statements in accordance with International Financial Reporting Standards (“IFRSs”) issued by the International Accounting Standards Board (“IASB”) and Interpretations issued by the IFRS Interpretations Committee (“IFRIC”).

#### New standards and interpretations adopted during the year

The following amendments to standards relevant to the Company’s operations were adopted during the year. Except where otherwise stated, the amendments to standards did not have a material impact on the Company’s financial statements.

Amendments to IAS 1 ‘*Presentation of Financial Statements*’ and IAS 8 ‘*Accounting Policies, Changes in Accounting Estimates and Errors*’: Definition of Material were issued by the IASB in October 2018, for application in accounting periods beginning on or after 1 January 2020.

There were no other standards, amendments to standards or interpretations relevant to the Company’s operations which were adopted during the year.

#### New standards and interpretations not yet adopted

At the date of authorisation of these financial statements, the following amendments to standards relevant to the Company’s operations were issued by the IASB but not mandatory for accounting periods beginning 1 January 2020. The Company does not expect that the adoption of the following amendments to standards will have a material impact on the Company’s financial statements.

Amendments to IAS 1 ‘*Presentation of Financial Statements*’: Classification of Liabilities as Current or Non-current were issued by the IASB in January 2020 and revised in July 2020, for retrospective application in accounting periods beginning on or after 1 January 2023.

As part of the 2018-2020 Annual Improvements Cycle published in May 2020, the IASB made an amendment to IFRS 9 ‘*Financial Instruments*’, relating to the treatment of fees in the assessment of whether financial liabilities are modified or exchanged, where such transactions occur on or after 1 January 2022. Early application is permitted.

# MORGAN STANLEY ASIA PRODUCTS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

### 2. BASIS OF PREPARATION (CONTINUED)

#### Basis of measurement

The financial statements of the Company are prepared under the historical cost basis, except for certain financial instruments that have been measured at fair value as explained in the accounting policies below.

#### Critical accounting judgements and key sources of estimation uncertainty

In preparing the financial statements, the Company makes judgements and estimates that affect the application of accounting policies and reported amounts.

Critical accounting judgements are key decisions made by management in the application of the Company's accounting policies, other than those involving estimations, which have the most significant effects on the amounts recognised in the financial statements.

Key sources of estimation uncertainty represent assumptions and estimations made by management that have a significant risk of resulting in a material adjustment to the carrying amount of assets and liabilities within the next financial year.

The critical judgements in applying the Company's accounting policies are for valuation of certain financial instruments. For further details on the judgements used in determining fair value of financial instruments, see note 3(d).

There are no key sources of estimation uncertainty in the reporting year that may have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities in the next financial year.

The Company evaluates the critical accounting judgements on an ongoing basis and believes that these are reasonable.

#### COVID-19

The COVID-19 pandemic and related voluntary and government-imposed social and business restrictions has adversely impacted global economic conditions, resulting in volatility in the global financial markets, increased unemployment, and operational challenges such as the temporary closure of businesses, sheltering-in-place directives and increased remote work protocols.

Governments around the world have been working to develop, manufacture, and distribute COVID-19 vaccines. Moreover, governments and central banks have reacted to the economic crisis caused by the pandemic by implementing stimulus and liquidity programs and cutting interest rates. If the pandemic is prolonged or the actions of governments and central banks are unsuccessful, including actions to facilitate the comprehensive distribution of effective vaccines, the adverse impact on the global economy will deepen, and the future results of operations and financial condition of Morgan Stanley and the Company may be adversely affected.

Should global market conditions worsen, or the pandemic lead to additional market disruptions, Morgan Stanley and the Group could experience reduced client activity and demand for products and services, impairments of other financial assets and other negative impacts on its financial position, including possible constraints on capital and liquidity, as well as a higher cost of capital, and possible changes or downgrades to credit ratings. A slowdown of commercial activity could cause overall sales and trading and investment banking revenues to decline and the decline in client balances could also reduce fee and financing revenues.

Although Morgan Stanley is unable to estimate the extent of the impact of the ongoing COVID-19 pandemic and related global economic crisis on future operating results, the high levels of client trading and capital markets activity experienced in the current year may not be repeated and certain other client-driven activity could be subdued.

## **MORGAN STANLEY ASIA PRODUCTS LIMITED**

### **NOTES TO THE FINANCIAL STATEMENTS**

**Year ended 31 December 2020**

#### **2. BASIS OF PREPARATION (CONTINUED)**

##### **COVID-19 (Continued)**

Morgan Stanley continue to be fully operational, with a vast majority of employees globally working from home as of 31 December 2020. Operationally, Morgan Stanley and the Company have initiated a work remotely protocol and restricted business travel of the workforce, with a return-to-workplace program, which is phased based on role, location and employee willingness and ability to return. While Morgan Stanley and the Company have not experienced a decrease in productivity as a result of the remote work environment, there can be no assurance that the transition will not have an adverse effect in the long term. If significant portions of our workforce, including key personnel, are unable to work effectively because of illness, government actions, or other restrictions in connection with the pandemic, the business impact of the pandemic could be exacerbated.

Morgan Stanley and the Company continue to use their Risk Management framework, including stress testing, to manage the significant uncertainty in the present economic and market conditions.

##### **The going concern assumption**

The Company's business activities, together with the factors likely to affect its future development, performance and position, are reflected in the Directors' Report on pages 1 to 6. In addition, the notes to the financial statements include the Company's objectives, policies and processes for managing its capital; its financial risk management objectives; details of its financial instruments; and its exposures to credit risk and liquidity risk.

As set out in the Directors' report retaining sufficient liquidity and capital to withstand market pressures remains central to the Morgan Stanley Group's strategy.

The Company's capital and liquidity is deemed sufficient to deal with both a normal and in a stressed market environment, including the current and potential stresses of COVID 19 for the foreseeable future. The existing and potential effects of COVID-19 on the business of the Company, as described in the 'COVID-19' note above, have been considered as part of the going concern analysis, including impact on the operational capacity of the business, access to liquidity and capital, contractual obligations, asset valuations and other critical accounting judgements and key sources of estimation uncertainty. The Company has access to further Morgan Stanley Group capital and liquidity as required.

Taking the above factors into consideration, the Directors believe it is reasonable to assume that the Company will have access to adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the annual report and financial statements.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

##### a. Functional currency

Items included in the financial statements are measured and presented in US dollars, the currency of the primary economic environment in which the Company operates.

Unless otherwise stated, all currency amounts in the financial statements and Directors' report are rounded to the nearest thousand US dollars.

##### b. Foreign currencies

All monetary assets and liabilities denominated in currencies other than US dollars are translated into US dollars at the rates ruling at the reporting date. Transactions and non-monetary assets and liabilities denominated in currencies other than US dollars are recorded at the rates prevailing at the dates of the transactions. All translation differences are taken through the statement of comprehensive income.

Exchange differences recognised in the statement of comprehensive income are presented in 'Other revenue' or 'Other expense', except where noted in 3(c) below.

##### c. Financial instruments

###### i) Financial instruments mandatorily at fair value through profit and loss

###### Trading financial instruments

Trading financial instruments comprising of listed and OTC derivative contracts, are initially recorded on trade date at fair value (see note 3(d) below). All subsequent changes in fair value and foreign exchange differences are reflected in the statement of comprehensive income in 'Net trading income/ (expense)'.

For all trading financial instruments, transaction costs are excluded from the initial fair value measurement of the financial instrument. These costs are recognised in the statement of comprehensive income in 'Other expense'.

###### Non-trading financial assets at FVPL

Non-trading financial assets at FVPL include prepaid equity securities contracts.

Non-trading financial assets at FVPL are principally financial assets where the Company makes decisions based upon the assets' fair value and are generally recognised on settlement date at fair value (see note 3(d) below), since they are neither regular way nor are they derivatives. From the date the terms are agreed (trade date), until the financial asset is funded (settlement date), the Company recognises any unrealised fair value changes in the financial asset as non-trading financial assets at FVPL. On settlement date, the fair value of consideration given is recognised as a non-trading financial asset at FVPL.

All subsequent changes in fair value and foreign exchange differences are reflected in the statement of comprehensive income in 'Net income/ (expense) from other financial instruments held at fair value'.

###### ii) Financial instruments designated at FVPL

Financial instruments designated at FVPL include loans, issued warrants and issued structured notes.

The Company has designated certain financial instruments at FVPL when the designation at fair value eliminates or significantly reduces an accounting mismatch which would otherwise arise. The Company has also designated certain financial liabilities at FVPL where the financial liability forms part of a group of financial assets or financial liabilities or both which are managed, evaluated and reported internally on a fair value basis.

From the date the transaction in a financial instrument designated at FVPL is entered into (trade date) until settlement date, the Company recognises any unrealised fair value changes in the contract as

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

##### c. Financial instruments (Continued)

##### ii) Financial instruments designated at FVPL (Continued)

financial instruments designated at FVPL in the statement of financial position. On settlement date, the fair value of consideration given or received is recognised as a financial instrument designated at FVPL (see note 3(d) below).

All subsequent changes in fair value, foreign exchange differences, interest are reflected in the statement of comprehensive income in 'Net income/ (expense) from other financial instruments held at fair value'.

See note 10 for an analysis of financial assets and financial liabilities designated at FVPL.

##### iii) Financial assets and financial liabilities at amortised cost

Financial assets at amortised cost include cash and trade and other receivables.

Financial assets are recognised at amortised cost when the Company's business model objective is to collect the contractual cash flows of the assets and where these cash flows are solely payments of principal and interest ("SPPI") on the principal amount outstanding until maturity. Such assets are recognised when the Company becomes a party to the contractual provisions of the instrument. The instruments are initially measured at fair value (see note 3(d) below) and subsequently measured at amortised cost less expected credit losses ("ECL") allowance. Interest is recognised in the statement of comprehensive income in 'Interest income', using the effective interest rate ("EIR") method as described below. Transaction costs that are directly attributable to the acquisition of the financial asset are added to the fair value on initial recognition. ECL and reversals thereof, if any, are recognised in the statement of comprehensive income in 'Net impairment loss on financial instruments'.

Financial liabilities classified at amortised cost include trade and other payables.

Financial liabilities are classified as being subsequently measured at amortised cost, except where they are held for trading or are designated as measured at FVPL. They are recognised when the Company becomes a party to the contractual provisions of the instrument and are initially measured at fair value (see note 3(d) below) and subsequently measured at amortised cost. Interest is recognised in the statement of comprehensive income in 'Interest expense' using the EIR method as described below. Transaction costs that are directly attributable to the issue of the financial liability are deducted from the fair value on initial recognition.

The EIR method is a method of calculating the amortised cost of a financial instrument (or a group of financial instruments) and of allocating the interest income or interest expense over the expected life of the financial instrument. The EIR is the rate that exactly discounts the estimated future cash payments and receipts through the expected life of the financial instrument (or, where appropriate a shorter period) to the carrying amount of the financial instrument. The EIR is established on initial recognition of the financial instrument. The calculation of the EIR includes all fees and commissions paid or received, transaction costs, and discounts or premiums that are an integral part of the EIR.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

##### d. Fair value

###### *Fair value measurement*

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. the “exit price”) in an orderly transaction between market participants at the measurement date.

Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, assumptions are set to reflect those that the Company believes market participants would use in pricing the asset or liability at the measurement date.

In determining fair value, the Company uses various valuation approaches and establishes a hierarchy for inputs used in measuring fair value that requires the most observable inputs be used when available.

Observable inputs are inputs that market participants would use in pricing the asset or liability that were developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect assumptions the Company believes other market participants would use in pricing the asset or liability, that are developed based on the best information available in the circumstances.

The fair value hierarchy is broken down into three levels based on the observability of inputs as follows, with Level 1 being the highest and Level 3 being the lowest level:

- Level 1 - Quoted prices (unadjusted) in an active market for identical assets or liabilities  
Valuations based on quoted prices in active markets that the Morgan Stanley Group has the ability for identical assets or liabilities. Valuation adjustments, block discounts and discounts for equity-specific restrictions that would not transfer to market participants are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgement.
- Level 2 - Valuation techniques using observable inputs  
Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
- Level 3 - Valuation techniques with significant unobservable inputs  
Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The availability of observable inputs can vary from product to product and is affected by a wide variety of factors, including the type of product, whether the product is new and not yet established in the marketplace, the liquidity of markets and other characteristics particular to the product. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorised in Level 3 of the fair value hierarchy.

The Company considers prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2 or from Level 2 to Level 3 of the fair value hierarchy.



## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

##### d. Fair value (Continued)

###### *Fair value measurement (Continued)*

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the total fair amount is disclosed in the level appropriate for the lowest level input that is significant to the total fair value of the asset or liability.

For assets and liabilities that are transferred between Levels in the fair value hierarchy during the period, fair values are ascribed as if the assets or liabilities had been transferred as of the beginning of the period.

###### *Valuation techniques*

Many cash instruments and OTC derivative contracts have bid and ask prices that can be observed in the marketplace. Bid prices reflect the highest price that a party is willing to pay for an asset. Ask prices represent the lowest price that a party is willing to accept for an asset. The Company carries positions at the point within the bid-ask range that meets its best estimate of fair value. For offsetting positions in the same financial instrument, the same price within the bid-ask spread is used to measure both the long and short positions.

Fair value for many cash instruments and OTC derivative contracts is derived using pricing models. Pricing models take into account the contract terms, as well as multiple inputs including, where applicable, commodity prices, equity prices, interest rate yield curves, credit curves, correlation, creditworthiness of the counterparty, creditworthiness of the Company, option volatility and currency rates.

Where appropriate, valuation adjustments are made to account for various factors such as liquidity risk (bid-ask adjustments), credit quality, model uncertainty and concentration risk and funding.

Adjustments for liquidity risk adjust model-derived mid-market amounts of Level 2 and Level 3 financial instruments for the bid-mid or mid-ask spread required to properly reflect the exit price of a risk position. Bid-mid and mid-ask spreads are marked to levels observed in trade activity, broker quotes or other external third-party data. Where these spreads are unobservable for the particular position in question, spreads are derived from observable levels of similar positions.

The Company applies credit-related valuation adjustments to structured notes which are designated at FVPL and to OTC derivative contracts. The Company considers the impact of changes in own credit spreads based upon observations of the secondary bond market spreads when measuring the fair value for structured notes.

For OTC derivative contracts, the impact of changes in both the Company's and the counterparty's credit rating is considered when measuring fair value. In determining the expected exposure the Company simulates the distribution of the future exposure to a counterparty, then applies market-based default probabilities to the future exposure, leveraging external third-party credit default swap ("CDS") spread data. Where CDS spread data are unavailable for a specific counterparty, bond market spreads, CDS spread data based on the counterparty's credit rating or CDS spread data that reference a comparable counterparty may be utilised. The Company also considers collateral held and legally enforceable master netting agreements that mitigate its exposure to each counterparty.

Adjustments for model uncertainty are taken for positions whose underlying models are reliant on significant inputs that are neither directly nor indirectly observable, hence requiring reliance on established theoretical concepts in their derivation. These adjustments are derived by making assessments of the possible degree of variability using statistical approaches and market-based information where possible.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

##### d. Fair value (Continued)

###### *Valuation process*

*Valuation Control* (“VC”) within Finance is responsible for the Company’s fair value valuation policies, processes and procedures. VC is independent of the business units and reports to the Chief Financial Officer of the Morgan Stanley Group (“CFO”), who has final authority over the valuation of the Company’s financial instruments. VC implements valuation control processes designed to validate the fair value of the Company’s financial instruments measured at fair value including those derived from pricing models.

###### *Model Review.*

VC, in conjunction with the Model Risk Management Department (“MRM”), which reports to the Chief Risk Officer of the Morgan Stanley Group (“CRO”), independently reviews valuation models’ theoretical soundness, the appropriateness of the valuation methodology and calibration techniques developed by the business units using observable inputs. Where inputs are not observable, VC reviews the appropriateness of the proposed valuation methodology to determine that it is consistent with how a market participant would arrive at the unobservable input. The valuation methodologies utilised in the absence of observable inputs may include extrapolation techniques and the use of comparable observable inputs. As part of the review, VC develops a methodology to independently verify the fair value generated by the business unit’s valuation models. The Company generally subjects valuations and models to a review process initially and on a periodic basis thereafter.

###### *Independent Price Verification.*

The business units are responsible for determining the fair value of financial instruments using approved valuation models and valuation methodologies. Generally on a monthly basis, VC independently validates the fair values of financial instruments determined using valuation models by determining the appropriateness of the inputs used by the business units and by testing compliance with the documented valuation methodologies approved in the model review process described above.

The results of this independent price verification and any adjustments made by VC to the fair value generated by the business units are presented to management of the Morgan Stanley Group’s three business segments (i.e. Institutional Securities, Wealth Management and Investment Management), the CFO and the CRO on a regular basis.

VC uses recently executed transactions, other observable market data such as exchange data, broker/ dealer quotes, third-party pricing vendors and aggregation services for validating the fair values of financial instruments generated using valuation models. VC assesses the external sources and their valuation methodologies to determine if the external providers meet the minimum standards expected of a third-party pricing source. Pricing data provided by approved external sources are evaluated using a number of approaches; for example, by corroborating the external sources’ prices to executed trades, by analysing the methodology and assumptions used by the external source to generate a price and/ or by evaluating how active the third-party pricing source (or originating sources used by the third-party pricing source) is in the market. Based on this analysis, VC generates a ranking of the observable market data designed to ensure that the highest-ranked market data source is used to validate the business unit’s fair value of financial instruments.

VC reviews the models and valuation methodology used to price new material Level 2 and Level 3 transactions and both Finance and MRM must approve the fair value of the trade that is initially recognised.

###### *Level 3 Transactions.*

VC reviews the business unit’s valuation techniques to assess whether these are consistent with market participant assumptions.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

##### d. Fair value (Continued)

###### *Gains and losses on inception*

In the normal course of business, the fair value of a financial instrument on initial recognition is the transaction price (i.e. the fair value of the consideration given or received). In certain circumstances, however, the fair value will be based on other observable current market transactions in the same instrument, without modification or repackaging, or on a valuation technique whose variables include only data from observable markets. When such evidence exists, the Company recognises a gain or loss on inception of the transaction.

When the use of unobservable market data has a significant impact on determining fair value at the inception of the transaction, the entire initial gain or loss indicated by the valuation technique as at the transaction date is not recognised immediately in the statement of comprehensive income, but is deferred and recognised over the life of the instrument or at the earlier of when the unobservable market data becomes observable, maturity or disposal of the instrument.

##### e. Derecognition of financial assets and liabilities

The Company derecognises a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risk and rewards of ownership of the asset.

Upon derecognition of a financial asset, the difference between the previous carrying amount and the sum of any consideration received, together with the transfer of any cumulative gain/ loss previously recognised in equity, are recognised in the statement of comprehensive income within 'Net gains/ (losses) on derecognition of financial assets measured at amortised cost'.

The Company derecognises financial liabilities when the Company's obligations are discharged, cancelled or they expire.

##### f. Impairment of financial instruments

The Company recognises loss allowances for ECL for financial assets measured at amortised cost.

###### *Measurement of ECL*

For financial assets, ECL are the present value of cash shortfalls (i.e. the difference between contractual and expected cash flows) over the expected life of the financial instrument, discounted at the asset's EIR.

Where a financial asset is credit-impaired at the reporting date, the ECL is measured as the difference between the asset's gross carrying amount and the present value of future cash flows, discounted at the original EIR.

The Company applies a three stage approach to measuring ECL based on the change in credit risk since initial recognition:

- Stage 1: if the credit risk of the financial instrument at the reporting date has not increased significantly since initial recognition, then the loss allowance is calculated as the lifetime cash shortfalls that will result if a default occurs in the next 12 months, weighted by the probability of that default occurring.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

##### f. Impairment of financial instruments (Continued)

###### *Measurement of ECL (Continued)*

- Stage 2: if there has been a significant increase in credit risk (“SICR”) since initial recognition, the loss allowance is calculated as the ECL over the remaining life of the financial instrument. If it is subsequently determined that there has no longer been a SICR since initial recognition, then the loss allowance reverts to reflecting 12 month expected losses.
- Stage 3: if there has been a SICR since initial recognition and the financial instrument is deemed credit-impaired (see below for definition of credit-impaired), the loss allowance is calculated as the ECL over the remaining life of the financial instrument. If it is subsequently determined that there has no longer been a SICR since initial recognition, then the loss allowance reverts to reflecting 12 month expected losses.

###### *Assessment of significant increase in credit risk*

When assessing SICR, the Company considers both quantitative and qualitative information and analysis based on the Company’s historical experience and expert credit risk assessment, including forward-looking information.

The probability of default (“PD”) is derived from internal credit rating grades (based on available information about the borrower) and multiple forward-looking macroeconomic scenarios which are probability weighted. Credit risk is considered to have increased significantly if the PD has significantly increased at the reporting date relative to the PD of the facility, at the date of initial recognition. The assessment of whether a change in PD is “significant” is based both on a consideration of the relative change in PD and on qualitative indicators of the credit risk of the facility, which indicate whether a loan is performing or in difficulty. In addition, as a backstop, the Company considers that SICR has occurred in all cases when an asset is more than 30 days past due.

The Company’s accounting policy is to not use the ‘low’ credit risk practical expedient. As a result, the Company monitors all financial instruments which are subject to impairment for SICR.

In general, ECLs are measured so that they reflect:

- a) A probability-weighted range of possible outcomes
- b) The time value of money; and
- c) Relevant information relating to past, current and future economic conditions.

###### *Calculation of ECL*

ECL is calculated using three main components:

- Probability of default (“PD”): for accounting purposes, the 12 month and lifetime PD represent the expected point-in-time probability of a default over the next 12 months and over the remaining lifetime of the financial instrument respectively, based on conditions existing at the balance sheet date and future economic conditions.
- Expected loss given default (“LGD”): the LGD represents expected loss conditional on default, taking into account the mitigating effect of collateral, including the expected value of the collateral when realised and the time value of money.
- Estimated exposure at default (“EAD”): this represents the expected EAD, taking into account the expected repayment of principal and interest from the balance sheet date to the default event together with any expected drawdowns of the facility over that period.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

##### f. Impairment of financial instruments (Continued)

###### *Calculation of ECL (Continued)*

These parameters are generally derived from internally developed statistical models, incorporating historical, current and forward-looking macro-economic data and country risk expert judgement. The macro-economic scenarios are reviewed quarterly.

The 12 month ECL are equal to the sum over the next 12 months of quarterly PD multiplied by LGD and EAD, with such expected losses being discounted at the EIR. Lifetime ECL are calculated using the discounted present value of total quarterly PDs multiplied by LGD and EAD, over the full remaining life of the facility.

When measuring ECL, the Company considers multiple scenarios, except where practical expedients are used to determine ECL. Practical expedients are used where they are consistent with the principles described above. ECL on certain trade receivables are calculated using a 'matrix' approach which reflects the previous history of credit losses on these financial assets, applying different provision levels based on the age of the receivable. Alternatively where there is a history of no credit losses, and where this is expected to persist into the future for structural or other reasons, such as collateral or other credit enhancements, it is determined that the ECL for a financial instrument are de minimis (highly immaterial) and it may not be necessary to recognise the ECL.

The Company measures ECL on an individual asset basis and has no purchased or originated credit-impaired ("POCI") financial assets.

###### *Presentation of ECL*

ECL, if any, is recognised in the statement of comprehensive income within 'Net impairment loss on financial instruments'. ECL on financial assets measured at amortised cost are presented as an ECL allowance. The allowance reduces the net carrying amount on the face of the statement of financial position.

###### *Credit-impaired financial instruments*

In assessing the impairment of financial instruments under the ECL model, the Company defines credit-impaired financial instruments in accordance with Credit Risk Management Department's policies and procedures. A financial instrument is credit-impaired when, based on current information and events, it is probable that the Company will be unable to collect all scheduled payments of principal or interest when due according to the contractual terms of the agreement.

###### *Definition of Default*

In assessing the impairment of financial instruments under the ECL model, the Company defines default in accordance with Credit Risk Management Department's policies and procedures. This considers whether the borrower is unlikely to pay its credit obligations to the Company in full and takes into account qualitative indicators, such as breaches of covenants. The definition of default also includes a presumption, that a financial asset which is more than 90 days past due ("DPD") has defaulted.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

##### f. Impairment of financial instruments (Continued)

###### *Write-offs*

Receivables are written off (either partially or in full) when they are deemed uncollectible which generally occurs when all commercially reasonable means of recovering the loan balance have been exhausted. Such determination is based on an indication that the borrower can no longer pay the obligation, or that the proceeds from collateral will not be sufficient to pay the loan. Partial write-offs are made when a portion of the receivable is uncollectable. However, financial assets that are written off could still be subject to enforcement activities for recoveries of amounts due. If the amount to be written off, if any, is greater than the accumulated loss allowance, the difference is reflected directly in the statement of comprehensive income within 'Net impairment loss on financial instruments' and is not recognised in the loss allowance account. Any subsequent recoveries are credited to 'Net impairment loss on financial instruments' within the statement of comprehensive income.

##### g. Cash and cash equivalents

Cash and cash equivalents comprise of cash, net of outstanding bank overdrafts, and are subject to insignificant risk of change in value.

##### h. Offsetting of financial assets and financial liabilities

Where there is a currently legally enforceable right to set off the recognised amounts and an intention to either settle on a net basis or to realise the asset and the liability simultaneously, financial assets and financial liabilities are offset and the net amount is presented on the statement of financial position. In the absence of such conditions, financial assets and financial liabilities are presented on a gross basis.

#### 4. NET TRADING EXPENSE

	<b>2020</b>	<b>2019</b>
	<b>US\$'000</b>	<b>US\$'000</b>
Net trading (expense)/income on bilateral OTC derivative contracts	(17,771)	3,673
Net trading income/(expense) on issued listed derivative contracts	23,195	(4,030)
Net trading (expense)/ income on other listed derivative contracts	(6,186)	224
	<u>(762)</u>	<u>(133)</u>

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 5. NET INCOME FROM OTHER FINANCIAL INSTRUMENTS HELD AT FAIR VALUE

	2020 US\$'000	2019 US\$'000
Net (losses)/ gains on:		
Non-trading financial assets at FVPL		
Prepaid equity securities contracts	(27,620)	43,034
Net gains/ (losses) on:		
Financial liabilities designated at FVPL		
Issued warrants	27,620	(43,034)
Issued structured notes	(3)	14
Financial assets designated at FVPL		
Loans		
Fair value gain/ (loss)	22	(22)
Interest income	7	19
	<u>27,646</u>	<u>(43,023)</u>
	<u>26</u>	<u>11</u>

#### 6. OTHER REVENUE

Other revenue represents management charges to the Company's direct parent undertaking for recovery of 'Other expense' given in note 8. Variance in management charges is due to the increase in other expense in current year.

#### 7. INTEREST INCOME

All interest income relates to financial assets at amortised cost and is calculated using the EIR method.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS Year ended 31 December 2020

#### 8. OTHER EXPENSE

	2020 US\$'000	2019 US\$'000
Fees paid to the stock exchange and other Morgan Stanley Group undertakings	10,273	-
Other	<u>24</u>	<u>-</u>
	<u>10,297</u>	<u>-</u>

The Company lists and issues derivative contracts on the Stock Exchange of Hong Kong (“the Exchange”). Fees paid to the stock exchange and other Morgan Stanley Group undertakings in above table represents fees incurred for listing and issuance of derivatives on the Exchange. In 2019, such fees was not material. Variance in fees paid of US\$10,273,000 is driven by the increase in the issuance of listed derivative contracts in current year.

#### 9. INCOME TAX

The Government of the Cayman Islands, has not, under existing legislation, imposed any income, corporate or capital gains tax, estate duty, inheritance tax, gift tax or withholding tax upon the Company.

#### 10. FINANCIAL ASSETS AND FINANCIAL LIABILITIES BY MEASUREMENT CATEGORY

The following table analyses financial assets and financial liabilities as presented in the statement of financial position by the IFRS 9 measurement classifications.

##### 31 December 2020

	FVPL (mandatorily) US\$'000	Amortised cost US\$'000	Total US\$'000
Cash	-	575	575
Trading financial assets	7,934	-	7,934
Trade and other receivables	<u>-</u>	<u>53,686</u>	<u>53,686</u>
Total financial assets	<u>7,934</u>	<u>54,261</u>	<u>62,195</u>
Trading financial liabilities	61,692	-	61,692
Trade and other payables	<u>-</u>	<u>453</u>	<u>453</u>
Total financial liabilities	<u>61,692</u>	<u>453</u>	<u>62,145</u>



## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 10. FINANCIAL ASSETS AND FINANCIAL LIABILITIES BY MEASUREMENT CATEGORY (CONTINUED)

31 December 2019	FVPL (mandatorily) US\$'000	FVPL (designated) US\$'000	Amortised cost US\$'000	Total US\$'000
Cash	-	-	600	600
Trading financial assets	3,991	-	-	3,991
Loans	-	468	-	468
Prepaid equity securities contracts	281,353	-	-	281,353
Trade and other receivables	-	-	11,559	11,559
Total financial assets	<u>285,344</u>	<u>468</u>	<u>12,159</u>	<u>297,971</u>
Trading financial liabilities	16,052	-	-	16,052
Issued warrants	-	281,353	-	281,353
Issued structured notes	-	467	-	467
Trade and other payables	-	-	49	49
Total financial liabilities	<u>16,052</u>	<u>281,820</u>	<u>49</u>	<u>297,921</u>

#### Financial assets and financial liabilities designated at FVPL

Financial assets and liabilities in the table above which are designated at FVPL consist primarily of the following financial assets and financial liabilities:

*Loans* – These are loans to other Morgan Stanley Group undertakings that, along with OTC derivative contracts which are classified as trading financial assets or liabilities, are part of the hedging strategy for the obligations arising pursuant to the issuance of the structured notes. Loans are designated at FVPL because the designation at FVPL eliminates or significantly reduces an accounting mismatch which would otherwise arise.

*Issued warrants* – These are zero strike price in nature involving the payment of an initial amount which approximates the fair values of the underlying equity securities at inception. These warrants are designated at FVPL as the risks to which the Company is a contractual party are risk managed on a fair value basis as part of the Company's trading portfolio and the risk is reported to key management personnel on this basis.

*Issued structured notes* – These relate to financial liabilities which arise from selling structured products generally in the form of notes or certificates. The structured notes are designated at FVPL as the risks to which the Company is a contractual party are risk managed on a fair value basis as part of the Company's trading portfolio and the risk is reported to key management personnel on this basis.

	2020		2019	
	Assets US\$'000	Liabilities US\$'000	Assets US\$'000	Liabilities US\$'000
Loans	-	-	468	-
Issued warrants	-	-	-	281,353
Issued structured notes	-	-	-	467
	<u>-</u>	<u>-</u>	<u>468</u>	<u>281,820</u>

In current year all issued warrants, structured notes and loans held have been matured. The maximum exposure to credit risk of financial assets which are designated at FVPL as at 31 December 2020 is US\$nil (2019: US\$468,000).

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 10. FINANCIAL ASSETS AND FINANCIAL LIABILITIES BY MEASUREMENT CATEGORY (CONTINUED)

##### Financial assets and financial liabilities designated at FVPL (continued)

There were no significant gains or losses attributable to changes in counterparty credit risk for financial assets designated at FVPL or in own credit risk for financial liabilities designated at FVPL for the year ended 31 December 2020 (2019 : US\$nil).

The Company determines the amount of changes in fair value attributable to changes in counterparty credit risk or own credit risk, as relating to financial assets and financial liabilities designated at FVPL, by first determining the fair value including the impact of counterparty credit risk or own credit risk, and then deducting those changes in fair value representing managed market risk. In determining fair value, the Company considers the impact of changes in own credit spreads based upon observations of the secondary bond market spreads when measuring the fair value for issued structured notes. The Company considers that this approach most faithfully represents the amount of change in fair value due to both counterparty credit risk and the Company's own credit risk.

The carrying amount of financial liabilities designated at FVPL for which all changes in fair value are presented through the statement of comprehensive income was same as the contractual amount due at maturity in current and prior year.

At initial recognition of a specific structured note issuance program, the Company's issuance process, and any planned hedging structure relating to the issuance of those structured notes, has been considered, to determine whether the presentation of fair value changes attributable to changes in the credit risk of those structured notes through other comprehensive income would create or enlarge an accounting mismatch in the statement of comprehensive income. If financial instruments, such as derivatives/ loans, measured at fair value for which changes in fair value incorporating counterparty credit risk are reflected within the statement of comprehensive income, are traded to economically hedge the structured note issuances in full, the fair value incorporating any counterparty credit risk ("CVA") arising on the hedging instruments may materially offset any DVA applied to structured notes, where the counterparties of the hedging instruments are part of the Morgan Stanley Group. In such cases, DVA of those structured notes is not reflected within other comprehensive income, and instead is presented in the statement of comprehensive income.

The Company's hedging structure is such that the fair value movements on the derivatives and loans, including CVA, are recognised in the statement of comprehensive income and offset the fair value movements including DVA on the issued structured notes. The counterparty credit risk of the hedging instruments is strongly correlated with the own credit risk of the Company, as the counterparties are members of the Morgan Stanley Group.

#### 11. TRADING FINANCIAL ASSETS AND LIABILITIES

Trading assets and trading liabilities are summarised as follows:

	2020		2019	
	Assets US\$'000	Liabilities US\$'000	Assets US\$'000	Liabilities US\$'000
Derivatives- Equity contracts				
Bilateral OTC derivative contracts	4,812	7,617	344	476
Issued listed derivative contracts	-	54,075	-	15,576
Other listed derivative contracts	3,122	-	3,647	-
	<u>7,934</u>	<u>61,692</u>	<u>3,991</u>	<u>16,052</u>

**MORGAN STANLEY ASIA PRODUCTS LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS**  
**Year ended 31 December 2020**

**12. TRADE AND OTHER RECEIVABLES**

	<b>2020</b> <b>US\$'000</b>	<b>2019</b> <b>US\$'000</b>
Trade receivables	7,433	785
Other receivables		
Amounts due from other Morgan Stanley Group undertakings	46,253	10,774
	<u>53,686</u>	<u>11,559</u>

**13. TRADE AND OTHER PAYABLES**

	<b>2020</b> <b>US\$'000</b>	<b>2019</b> <b>US\$'000</b>
Trade payables	296	-
Other payables		
Amounts due to other Morgan Stanley Group undertakings	157	49
	<u>453</u>	<u>49</u>

**14. EQUITY**

		<b>Ordinary shares of US\$1 each Number</b>
<b>Authorised</b>		
At 1 January 2019, 31 December 2019 and 31 December 2020		<u>50,000</u>
	<b>Ordinary shares of US\$1 each Number</b>	<b>US\$</b>
<b>Issued and fully paid</b>		
At 1 January 2019, 31 December 2019 and 31 December 2020	<u>50,000</u>	<u>50,000</u>

The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled, on a show of hands, to one vote and, on a poll, one vote per share at meetings of shareholders of the Company. All shares rank equally with regard to the Company's residual assets.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 15. ADDITIONAL CASH FLOW INFORMATION

##### a. Cash and cash equivalents

For the purposes of the statement of cash flows, cash and cash equivalents comprise cash, which have less than three months maturity from the date of acquisition.

##### b. Reconciliation of cash flows from operating activities

	2020	2019
	US\$'000	US\$'000
Result for the year	-	-
<i>Adjustments for:</i>		
Net trading expense	762	133
Net income from other financial instruments held at fair value	(26)	(11)
Interest income	(736)	(122)
Other revenue	(10,297)	-
Other expense	10,297	-
Operating cash flows before changes in operating assets and liabilities	<u>-</u>	<u>-</u>
Changes in operating assets		
Increase in trading financial assets	(3,943)	(3,991)
Increase in trade and other receivables	(7,012)	(1,048)
	<u>(10,955)</u>	<u>(5,039)</u>
Changes in operating liabilities		
Increase in trading financial liabilities	45,640	16,052
Increase/ (decrease) in trade and other payables	404	(881)
	<u>46,044</u>	<u>15,171</u>
<b>Net cash flows from operating activities</b>	<u><u>35,089</u></u>	<u><u>10,132</u></u>

**MORGAN STANLEY ASIA PRODUCTS LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS**

**Year ended 31 December 2020**

**15. ADDITIONAL CASH FLOW INFORMATION (CONTINUED)**

**c. Reconciliation of liabilities arising from financing activities**

	Balance at 1	Cash flows	Non-cash changes		Balance at
	January		Foreign exchange revaluation	Fair value changes	31
	2020	US\$'000			US\$'000
	US\$'000	US\$'000	US\$'000	US\$'000	2020
Issued warrants	281,353	(251,514)	-	(29,839)	-
Issued structured notes	467	(469)	(1)	3	-
<b>Total liabilities from financing activities</b>	<b>281,820</b>	<b>(251,983)</b>	<b>(1)</b>	<b>(29,836)</b>	<b>-</b>
	Balance at 1	Cash flows	Non-cash changes		Balance at
	January		Foreign exchange revaluation	Fair value changes	31
	2019	US\$'000			US\$'000
	US\$'000	US\$'000	US\$'000	US\$'000	2019
Issued warrants	285,269	(41,823)	127	37,780	281,353
Issued structured notes	1,863	(1,383)	-	(13)	467
<b>Total liabilities from financing activities</b>	<b>287,132</b>	<b>(43,206)</b>	<b>127</b>	<b>37,767</b>	<b>281,820</b>

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 16. EXPECTED MATURITY OF ASSETS AND LIABILITIES

The table below shows an analysis of assets and liabilities analysed according to when they are expected to be recovered, realised or settled.

At 31 December 2020

	Less than or equal to twelve months US\$'000	More than twelve months US\$'000	Total US\$'000
<b>ASSETS</b>			
Cash	575	-	575
Trading financial assets	5,634	2,300	7,934
Trade and other receivables	53,686	-	53,686
	<u>59,895</u>	<u>2,300</u>	<u>62,195</u>
<b>LIABILITIES</b>			
Trading financial liabilities	49,391	12,301	61,692
Trade and other payables	453	-	453
	<u>49,844</u>	<u>12,301</u>	<u>62,145</u>

At 31 December 2019

<b>ASSETS</b>			
Cash	600	-	600
Trading financial assets	454	3,537	3,991
Loans	468	-	468
Prepaid equity securities contracts	276,087	5,266	281,353
Trade and other receivables	11,559	-	11,559
	<u>289,168</u>	<u>8,803</u>	<u>297,971</u>
<b>LIABILITIES</b>			
Trading financial liabilities	7,000	9,052	16,052
Issued warrants	276,087	5,266	281,353
Issued structured notes	467	-	467
Trade and other payables	49	-	49
	<u>283,603</u>	<u>14,318</u>	<u>297,921</u>

## **MORGAN STANLEY ASIA PRODUCTS LIMITED**

### **NOTES TO THE FINANCIAL STATEMENTS**

**Year ended 31 December 2020**

#### **17. SEGMENT REPORTING**

Segment information is presented in respect of the Company's business and geographical segments. The business and geographical segments are based on the Company's management and internal reporting structure.

##### ***Business segment***

Morgan Stanley structures its business segments primarily based upon the nature of the financial products and services provided to customers and Morgan Stanley's internal management structure. The Company's own business segment is consistent with that of Morgan Stanley.

The Company has one reportable business segment, Institutional Securities which includes the issuance of structured products and the hedging of the obligations arising pursuant to such issuance.

##### ***Geographical segment***

The Company operates in one geographic region, Asia. The basis for attributing external revenue and total assets to one geographic region is determined by trading desk location.

#### **18. FINANCIAL RISK MANAGEMENT**

##### **Risk management procedures**

Risk is an inherent part of both the Morgan Stanley Group's and the Company's business activity and is managed by the Company within the context of the broader Morgan Stanley Group. The Morgan Stanley Group seeks to identify, assess, monitor and manage each of the various types of risk involved in its business activities in accordance with defined policies and procedures. The Company's own risk management policies and procedures are consistent with those of the Morgan Stanley Group.

The principal activity of the Company continues to be the issuance of financial instruments under an Issuance Programme and the economic hedging of the obligations arising pursuant to such issuances. It is the policy and objective of the Company not to be exposed to market risk as a result of its issuance activities. On the issuance of each financial instrument, the Company enters into economic hedges of its obligations by purchasing financial instruments from another Morgan Stanley Group entity and from the market.

Significant risks faced by the Company resulting from its issuance activities and hedging strategies are set out below.

##### **Credit risk**

Credit risk refers to the risk of loss arising when a borrower, counterparty or issuer does not meet its financial obligations to the Company.

##### **Credit risk management**

Credit risk exposure is managed on a global basis and in consideration of each significant legal entity within the Morgan Stanley Group. The credit risk management policies and procedures establish the framework for identifying, measuring, monitoring and controlling credit risk whilst ensuring transparency of material credit risks, compliance with established limits and escalating risk concentrations to appropriate senior management.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 18. FINANCIAL RISK MANAGEMENT (CONTINUED)

##### Credit risk management (Continued)

The Company may incur credit risk in its warrant issuance business through a variety of activities, including, but not limited to, the following:

- entering into derivative contracts under which counterparties may have obligations to make payments to the Company;
- providing short or long-term funding to Morgan Stanley Group undertakings;

The Company hedges all of its financial liabilities by entering into prepaid OTC contracts with its immediate parent and OTC derivative contracts with other Morgan Stanley Group undertakings. Except for cash and certain listed derivative contracts, the Company enters into all of its financial asset transactions with other Morgan Stanley Group undertakings, and both the Company and the other Morgan Stanley Group undertakings are wholly owned subsidiaries of the same ultimate parent entity, Morgan Stanley. As a result of the implicit support that would be provided by Morgan Stanley, the Company is considered exposed to the credit risk of Morgan Stanley, except where the Company transacts with other Morgan Stanley Group undertakings that have a higher credit rating to that of Morgan Stanley.

##### Exposure to credit risk and exposure to credit risk by internal rating grades

The maximum exposure to credit risk (“gross credit exposure”) of the Company as at 31 December 2020 is disclosed below, based on the carrying amounts of the financial assets which the Company believes are subject to credit risk. The table includes financial instruments subject to ECL and not subject to ECL. Those financial instruments that bear credit risk but are not subject to ECLs are subsequently measured at fair value. The table below does not include receivables arising from pending securities transactions with market counterparties as credit risk is considered to be insignificant. Where the Company enters into credit enhancements, including receiving cash and security as collateral and master netting agreements, to manage the credit exposure on these financial instruments the financial effect of the credit enhancements is also disclosed in note 19 ‘*Financial Assets and Financial Liabilities Subject to Offsetting*’.

The Company does not have any exposure arising from items not recognised on the balance sheet.

The Company does not hold financial assets considered to be credit-impaired.

The following table provides an analysis of the credit risk exposure by ECL stage per class of recognised and unrecognised financial instrument subject to ECL, based on the following internal credit rating grades:

Investment grade: internal grades AAA - BBB

Non-investment grade: internal grades BB - CCC

Default: internal grades D

Internal credit ratings are derived using methodologies generally consistent with those used by external agencies.



## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 18. FINANCIAL RISK MANAGEMENT (CONTINUED)

##### Exposure to credit risk and exposure to credit risk by internal rating grades (Continued)

2020	Gross credit exposure <sup>(1)(2)</sup> US\$'000	Counterparty	Rating	Credit grade
<b>Subject to ECL<sup>(3)(4)</sup>:</b>				
Cash	76	Standard Chartered Bank	A	Investment Grade
	52	ANZ Bank Limited	A	Investment Grade
	172	The Hong Kong and Shanghai Banking Corporation Limited	A	Investment Grade
	275	Sumitomo Mitsui Banking Corp	A	Investment Grade
<b>Total Cash</b>	<b>575</b>			
Trade and other receivables	46,253	MSASP Morgan Stanley & Co. International plc ("MSIP")	BBB	Investment Grade
	6,508		A	Investment Grade
<b>Total trade and other receivables</b>	<b>52,761</b>			
<b>Not subject to ECL<sup>(5)</sup>:</b>				
Trading financial assets	4,812	MSIP Hong Kong Securities Clearing Company Limited ("HKSCC")	A	Investment Grade
	3,122		A	Investment Grade
<b>Total trading financial assets</b>	<b>7,934</b>			

- (1) The carrying amount recognised in the statement of financial position best represents the Company's maximum exposure to credit risk.
- (2) Of the gross credit exposure, intercompany cross product netting arrangements are in place which would allow for an additional US\$ 8,021,000 to be offset in the ordinary course of business and/ or in the event of default as disclosed in note 19 financial assets and financial liabilities subject to offsetting.
- (3) Both cash and trade and other receivables are at Stage 1.
- (4) There is minimal ECL of US\$24,000 on trade and other receivables.
- (5) Financial assets measured at FVPL are not subject to ECL.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 18. FINANCIAL RISK MANAGEMENT (CONTINUED)

##### Exposure to credit risk and exposure to credit risk by internal rating grades (Continued)

2019	Gross credit exposure <sup>(1)(2)</sup> US\$'000	Counterparty	Rating	Credit grade
<b>Subject to ECL<sup>(3)(4)</sup>:</b>				
Cash	85	Standard Chartered Bank	A	Investment Grade
	48	ANZ Bank Limited	A	Investment Grade
	210	The Hong Kong and Shanghai Banking Corporation Limited	A	Investment Grade
	257	Sumitomo Mitsui Banking Corp	A	Investment Grade
<b>Total Cash</b>	<b>600</b>			
Trade and other receivables	10,774	MSASP	BBB	Investment Grade
	118	MSIP	A	Investment Grade
<b>Total trade and other receivables</b>	<b>10,892</b>			
<b>Not subject to ECL<sup>(5)</sup>:</b>				
Trading financial assets	344	MSIP	A	Investment Grade
	3,647	Hong Kong Securities Clearing Company Limited ("HKSCC")	A	Investment Grade
<b>Total trading financial assets</b>	<b>3,991</b>			
Loans	468	Morgan Stanley International Finance S.A.	BBB	Investment Grade
Prepaid equity securities contracts	281,353	MSASP	BBB	Investment Grade

- (1) The carrying amount recognised in the statement of financial position best represents the Company's maximum exposure to credit risk.
- (2) Of the gross credit exposure, intercompany cross product netting arrangements are in place which would allow for an additional US\$ 154,328,000 to be offset in the ordinary course of business and/ or in the event of default as disclosed in note 19 financial assets and financial liabilities subject to offsetting.
- (3) Both cash and trade and other receivables are at Stage 1.
- (4) There is no ECL on cash and trade and other receivables.
- (5) Financial assets measured at FVPL are not subject to ECL.

#### Liquidity risk

Liquidity risk refers to the risk that the Company will be unable to finance its operations due to a loss of access to the capital markets or difficulty in liquidating its assets. Liquidity risk encompasses the Company's ability (or perceived ability) to meet its financial obligations without experiencing significant business disruption or reputational damage that may threaten the Company's viability as a going concern.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 18. FINANCIAL RISK MANAGEMENT (CONTINUED)

##### Liquidity risk (Continued)

Liquidity risk also encompasses the associated funding risks triggered by the market or idiosyncratic stress events that may cause unexpected changes in funding needs or an inability to raise new funding. Generally, the Company incurs liquidity risk as a result of its trading, lending and investing activities.

The Company's liquidity risk management policies and procedures are consistent with those of the Morgan Stanley Group.

The primary goal of Morgan Stanley Group's liquidity risk and funding management framework is to ensure that the Company has access to adequate funding across a wide range of market conditions and time horizons. The framework is designed to enable the Company to fulfil its financial obligations and support the execution of its business strategies.

The following principles guide the Morgan Stanley Group's liquidity risk management framework:

- Sufficient liquid assets should be maintained to cover maturing liabilities and other planned and contingent outflows;
- Maturity profile of assets and liabilities should be aligned, with limited reliance on short-term funding;
- Source, counterparty, currency, region, and term of funding should be diversified; and
- Liquidity Stress Tests should anticipate, and account for, periods of limited access to funding.

The Company hedges all of its financial liabilities by entering into prepaid OTC contracts with its immediate parent and OTC derivative contracts with other Morgan Stanley Group undertakings. In general, the maturity profile of the financial assets matches the maturity profile of the financial liabilities.

The core components of the Morgan Stanley Group's liquidity management framework, which includes consideration of the liquidity risk for each individual legal entity, are the Required Liquidity Framework, Liquidity Stress Tests and the Global Liquidity Reserve, which support the Morgan Stanley Group's target liquidity profile.

##### *Required Liquidity Framework*

The Required Liquidity Framework establishes the amount of liquidity the Morgan Stanley Group must hold in both normal and stressed environments to ensure that its financial condition and overall soundness is not adversely affected by an inability (or perceived inability) to meet its financial obligations in a timely manner. The Required Liquidity Framework considers the most constraining liquidity requirement to satisfy all regulatory and internal limits.

##### *Liquidity Stress Tests*

The Morgan Stanley Group uses Liquidity Stress Tests to model external and intercompany liquidity flows across multiple scenarios and a range of time horizons. These scenarios contain various combinations of idiosyncratic and systemic stress events of different severity and duration. The methodology, implementation, production and analysis of the Liquidity Stress Tests are important components of the Required Liquidity Framework.

The Liquidity Stress Tests are produced for Morgan Stanley and its major operating subsidiaries, as well as at major currency levels, to capture specific cash requirements and cash availability at various legal entities. The Liquidity Stress Tests assume that subsidiaries will use their own liquidity first to fund their obligations before drawing liquidity from Morgan Stanley. It is also assumed that Morgan Stanley will support its subsidiaries and will not have access to cash that may be held at certain subsidiaries. In addition to the assumptions underpinning the Liquidity Stress Tests, the Morgan Stanley Group takes into

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 18. FINANCIAL RISK MANAGEMENT (CONTINUED)

##### Liquidity risk (Continued)

###### *Liquidity Stress Tests (continued)*

consideration the settlement risk related to intra-day settlement and clearing of securities and financial activities.

Since the Company hedges the risk of its financial liabilities with financial assets that match the maturity profile of the financial liabilities, the Company is not considered a major operating subsidiary for the purposes of liquidity risk. However, the Company would have access to the cash or liquidity reserves held by Morgan Stanley in the unlikely event that it was unable to access adequate financing to service its financial liabilities when they become payable.

The Required Liquidity Framework and Liquidity Stress Tests are evaluated on an ongoing basis and reported to the Firm Risk Committee, Asset/Liability Management Committee, and other appropriate risk committees.

###### *Global Liquidity Reserve*

The Morgan Stanley Group maintains sufficient liquidity reserves (the “Global Liquidity Reserve”) to cover daily funding needs and to meet strategic liquidity targets sized by the Required Liquidity Framework and Liquidity Stress Tests. The size of the Global Liquidity Reserve is actively managed by the Morgan Stanley Group considering the following components: unsecured debt maturity profile; balance sheet size and composition; funding needs in a stressed environment inclusive of contingent cash outflows; and collateral requirements. In addition, the Morgan Stanley Group’s Global Liquidity Reserve includes a discretionary surplus based on the Morgan Stanley Group’s risk tolerance and is subject to change depending on market and firm-specific events.

The Morgan Stanley Group’s Global Liquidity Reserve, to which the Company has access, is held within Morgan Stanley and its major operating subsidiaries and is composed of diversified cash and cash equivalents and unencumbered highly liquid securities.

Eligible unencumbered highly liquid securities including US government securities, US agency securities, US agency mortgage-backed securities, non-US government securities and other highly liquid investment grade securities.

The ability to monetise assets during a liquidity crisis is critical. The Morgan Stanley Group believes that the assets held in its Global Liquidity Reserve can be monetised within five business days in a stressed environment given the highly liquid and diversified nature of the reserves.

###### *Funding management*

The Morgan Stanley Group manages its funding in a manner that reduces the risk of disruption to the Morgan Stanley Group’s and the Company’s operations. The Morgan Stanley Group pursues a strategy of diversification of secured and unsecured funding sources (by product, investor and region) and attempts to ensure that the tenor of the Morgan Stanley Group’s, and the Company’s, liabilities equals or exceeds the expected holding period of the assets being financed.

The Morgan Stanley Group funds its balance sheet on a global basis through diverse sources, which includes consideration of the funding risk of each legal entity. These sources include the Morgan Stanley Group’s equity capital, long-term borrowing, securities sold under agreements to repurchase (“repurchase agreements”), securities lending, deposits, letters of credit and lines of credit.

The Morgan Stanley Group has active financing programmes for both standard and structured products, targeting global investors and currencies.

# MORGAN STANLEY ASIA PRODUCTS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

### 18. FINANCIAL RISK MANAGEMENT (CONTINUED)

#### Liquidity risk (Continued)

##### Balance sheet management

In managing both the Morgan Stanley Group's and the Company's funding risk, the composition and size of the entire balance sheet, not just financial liabilities, is monitored and evaluated. The liquid nature of the marketable securities and short-term receivables arising principally from sales and trading activities in Institutional Securities business provides the Morgan Stanley Group and the Company with flexibility in managing the size of its balance sheet.

##### Maturity analysis

In the following maturity analysis of financial assets and financial liabilities, derivative contracts, prepaid equity securities contracts, loans, issued warrants and issued structured notes are disclosed according to their earliest contractual maturity; all such amounts are presented at their fair value, consistent with how these financial instruments are managed. All other amounts represent undiscounted cash flows receivable and payable by the Company arising from its financial assets and financial liabilities to earliest contractual maturities as at 31 December 2020 and 31 December 2019. Receipts of financial assets and repayments of financial liabilities that are subject to immediate notice are treated as if notice were given immediately and are classified as on demand. This presentation is considered by the Company to appropriately reflect the liquidity risk arising from these financial assets and financial liabilities, presented in a way that is consistent with how the liquidity risk on these financial assets and financial liabilities is managed by the Company.

	<b>On demand US\$'000</b>	<b>Less than 1 month US\$'000</b>	<b>1 month - 3 months US\$'000</b>	<b>3 months - 1 year US\$'000</b>	<b>1 year - 5 years US\$'000</b>	<b>Total US\$'000</b>
<b>31 December 2020</b>						
<b>Financial assets</b>						
Cash	575	-	-	-	-	575
Trading financial assets	-	1,867	429	3,338	2,300	7,934
Trade and other receivables <sup>(1)</sup>	8,518	-	-	-	45,168	53,686
<b>Total financial assets</b>	<u>9,093</u>	<u>1,867</u>	<u>429</u>	<u>3,338</u>	<u>47,468</u>	<u>62,195</u>
<b>Financial liabilities</b>						
Trading financial liabilities	-	8,867	12,545	27,979	12,301	61,692
Trade and other payables	453	-	-	-	-	453
<b>Total financial liabilities</b>	<u>453</u>	<u>8,867</u>	<u>12,545</u>	<u>27,979</u>	<u>12,301</u>	<u>62,145</u>
<b>31 December 2019</b>						
<b>Financial assets</b>						
Cash	600	-	-	-	-	600
Trading financial assets	-	-	-	454	3,537	3,991
Loans	-	-	-	468	-	468
Prepaid equity securities contracts	-	-	20,247	255,840	5,266	281,353
Trade and other receivables	1,507	-	-	-	10,052	11,559
<b>Total financial assets</b>	<u>2,107</u>	<u>-</u>	<u>20,247</u>	<u>256,762</u>	<u>18,855</u>	<u>297,971</u>
<b>Financial liabilities</b>						
Trading financial liabilities	-	956	463	5,581	9,052	16,052
Issued warrants	-	45,405	20,247	210,435	5,266	281,353
Issued structured notes	-	-	-	467	-	467
Trade and other payables	49	-	-	-	-	49
<b>Total financial liabilities</b>	<u>49</u>	<u>46,361</u>	<u>20,710</u>	<u>216,483</u>	<u>14,318</u>	<u>297,921</u>

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 18. FINANCIAL RISK MANAGEMENT (CONTINUED)

##### Liquidity risk (Continued)

###### *Maturity analysis (Continued)*

- (1) Trade and other receivables include certain receivables due from the Company's direct parent undertaking which is dated on a rolling 395 day terms and includes a voluntary bilateral early settlement provision. Although these receivables are disclosed based on the required contractual maturity excluding the effect of voluntary bilateral early settlement provision, it is expected early repayment can be agreed with the Company's direct parent undertaking if required.

##### Market risk

Market risk is identified by IFRS 7 '*Financial instruments: Disclosures*' ("IFRS 7") as the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices.

The listed issued derivative contracts, issued warrants and issued structured notes expose the Company to the risk of changes in market prices of the underlying securities, interest rate risk and, where denominated in currencies other than US dollars, the risk of changes in rates of exchange between the US dollar and the other relevant currencies. The Company uses the risk mirroring contracts that it purchases from other Morgan Stanley Group undertakings to match the price risk, foreign currency and other market risks associated with the issuance of the warrants and structured notes, consistent with the Company's risk management strategy. As such, the Company is not exposed to any net market risk on these financial instruments. Different components of market risks from the issued securities resulting into price movements in underlying securities, exchange rates and others will be offset by the same but opposite price movements in the risk-mirroring contracts. Due to Company's hedging strategy, the gain in the equity price sensitivity analysis as shown in table below will be hedged and offset by fair value movements into risk-mirroring contracts.

Sound market risk management is an integral part of the Company's and Morgan Stanley Group's culture. The Company is responsible for ensuring that market risk net exposures are well managed, monitored and remain flat. The Company also ensures transparency of material market risks, monitors compliance with established limits, and escalates risk concentrations to appropriate senior management.

The market price risk exposure from the financial assets is mainly equity price risk, interest rate risk and currency risk, although all such risks are offset by equal and offsetting exposure to risk on the issued securities. Equity price risk refers to the risk of changes in the equity price of the assets underlying these financial assets.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 18. FINANCIAL RISK MANAGEMENT (CONTINUED)

##### Market risk (Continued)

###### *Equity price sensitivity analysis*

The sensitivity analysis below is determined based on the exposure to equity price risk at 31 December 2020 and 31 December 2019 respectively.

The market risk related to such equity price risk is measured by estimating the potential reduction in total comprehensive income associated with a 10% decline in the underlying asset values as shown in the table below.

	<i>Impact on Total Comprehensive Income Gains/(losses)</i>	
	<b>2020</b>	<b>2019</b>
	<b>US\$'000</b>	<b>US\$'000</b>
Trading financial assets	(793)	(399)
Prepaid equity securities contracts	-	(28,135)
Trading financial liabilities	6,169	1,605
Issued warrants	-	28,135
	<u>5,376</u>	<u>1,206</u>

The Company's equity price risk is mainly concentrated on equity securities in Asia.

###### *Interest rate risk*

Interest rate risk is defined by IFRS 7 'Financial instruments: Disclosures' ("IFRS 7") as the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is primarily exposed to interest rate risk under this definition as a result of changes in the future cash flows of floating rate intercompany loans held at amortised cost and at fair value.

The application of a parallel shift in market interest rates of 50bp increase or decrease to these positions, would result in a net gain or loss of approximately US\$741 (2019: US\$160) in the statement of comprehensive income.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 19. FINANCIAL ASSETS AND FINANCIAL LIABILITIES SUBJECT TO OFFSETTING

In order to manage credit exposure arising from its business activities, the Company applies various credit risk management policies and procedures, see note 18 for further details. Primarily in connection with the issuance and hedging activities, the Company enters into master netting arrangements and collateral arrangements with certain counterparties. These agreements provide the Company with the right, in the ordinary course of business and/ or in the event of a counterparty default (such as bankruptcy or a counterparty's failure to pay or perform), to net a counterparty's rights and obligations under such agreement and, in the event of counterparty default, set off collateral held by the Company against the net amount owed by the counterparty.

In the statement of financial position, financial assets and financial liabilities are only offset and presented on a net basis where there is a current legally enforceable right to set off the recognised amounts and an intention to either settle on a net basis or to realise the assets and the liabilities simultaneously. In the absence of such conditions, financial assets and financial liabilities are presented on a gross basis.

The following tables present information about offsetting of financial instruments.

	<b>Gross amounts</b>	<b>Amounts offset in</b>	<b>Net amounts</b>
	<b>US\$'000</b>	<b>the statement of</b>	<b>presented in the</b>
		<b>financial position</b>	<b>statement of</b>
		<b>US\$'000</b>	<b>financial position</b>
			<b>US\$'000</b>
<b>31 December 2020</b>			
<b>Assets</b>			
Trading financial assets	7,934	-	7,934
Trade and other receivables	53,686	-	53,686
<b>TOTAL</b>	<b>61,620</b>	<b>-</b>	<b>61,620</b>
<b>Liabilities</b>			
Trading financial liabilities	61,692	-	61,692
Trade and other payables	453	-	453
<b>TOTAL</b>	<b>62,145</b>	<b>-</b>	<b>62,145</b>



**MORGAN STANLEY ASIA PRODUCTS LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS**

**Year ended 31 December 2020**

**19. FINANCIAL ASSETS AND FINANCIAL LIABILITIES SUBJECT TO OFFSETTING  
(CONTINUED)**

	Net amounts presented in the statement of financial position US\$'000	Amounts not offset in the statement of financial position <sup>(1)</sup>		Net exposure US\$'000
		Financial instruments US\$'000	Cash collateral <sup>(2)</sup> US\$'000	
<b>31 December 2020</b>				
<b>Assets</b>				
MSIP	11,320	(4,812)	(2,805)	3,703
MSASP	46,253	-	-	46,253
Others	4,047	(404)	-	3,643
<b>TOTAL</b>	<b>61,620</b>	<b>(5,216)</b>	<b>(2,805)</b>	<b>53,599</b>
<b>Liabilities</b>				
MSIP	7,617	(7,617)	-	-
Morgan Stanley & Co. LLC	49	-	-	49
Others	54,479	(404)	-	54,075
<b>TOTAL</b>	<b>62,145</b>	<b>(8,021)</b>	<b>-</b>	<b>54,124</b>

(1) These are amounts that would be offset in the ordinary course of business and/ or in the event of default according to the intercompany cross-product legally enforceable netting arrangements with the respective Morgan Stanley Group undertakings.

(2) The cash collateral not offset is recognized in the statement of financial position within Trade and other receivables.

**MORGAN STANLEY ASIA PRODUCTS LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS**

**Year ended 31 December 2020**

**19. FINANCIAL ASSETS AND FINANCIAL LIABILITIES SUBJECT TO OFFSETTING  
(CONTINUED)**

	Gross amounts US\$'000	Amounts offset in the statement of financial position US\$'000	Net amounts presented in the statement of financial position US\$'000
<b>31 December 2019</b>			
<b>Assets</b>			
Trading financial assets	3,991	-	3,991
Loans	468	-	468
Prepaid equity securities contracts	281,353	-	281,353
Trade and other receivables	11,559	-	11,559
<b>TOTAL</b>	<b>297,371</b>	<b>-</b>	<b>297,371</b>
<b>Liabilities</b>			
Trading financial liabilities	16,052	-	16,052
Issued warrants	281,353	-	281,353
Issued structured notes	467	-	467
Trade and other payables	49	-	49
<b>TOTAL</b>	<b>297,921</b>	<b>-</b>	<b>297,921</b>

**MORGAN STANLEY ASIA PRODUCTS LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS**

**Year ended 31 December 2020**

**19. FINANCIAL ASSETS AND FINANCIAL LIABILITIES SUBJECT TO OFFSETTING  
(CONTINUED)**

	Net amounts presented in the statement of financial position US\$'000	Amounts not offset in the statement of financial position <sup>(1)</sup>		Net exposure US\$'000
		Financial instruments US\$'000	Cash collateral <sup>(2)</sup> US\$'000	
<b>31 December 2019</b>				
<b>Assets</b>				
MSIP	462	(344)	(118)	-
MSASP	292,127	(153,866)	-	138,261
Morgan Stanley International Finance S.A.	468	-	-	468
Others	4,314	-	-	4,314
<b>TOTAL</b>	<b>297,371</b>	<b>(154,210)</b>	<b>(118)</b>	<b>143,043</b>
<b>Liabilities</b>				
MSIP	476	(344)	(118)	14
MSASP	153,866	(153,866)	-	-
Morgan Stanley & Co. LLC	47	-	-	47
Others	143,532	-	-	143,532
<b>TOTAL</b>	<b>297,921</b>	<b>(154,210)</b>	<b>(118)</b>	<b>143,593</b>

(1) These are amounts that would be offset in the ordinary course of business and /or in the event of default according to the intercompany cross-product legally enforceable netting arrangements with the respective Morgan Stanley Group undertakings.

(2) The cash collateral not offset is recognized in the statement of financial position within Trade and other receivables

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 20. ASSETS AND LIABILITIES MEASURED AT FAIR VALUE

##### a. Financial assets and liabilities recognised at fair value on a recurring basis

The following tables present the carrying value of the Company's financial assets and financial liabilities recognised at fair value on a recurring basis, classified according to the fair value hierarchy.

	Quoted prices in active market (Level 1) US\$'000	Valuation techniques using observable inputs (Level 2) US\$'000	Valuation techniques with significant unobservable inputs (Level 3) US\$'000	Total US\$'000
<b>2020</b>				
Trading financial assets	3,122	4,812	-	7,934
Trading financial liabilities	3,001	58,691	-	61,692
<b>2019</b>				
Trading financial assets	3,647	344	-	3,991
Loans	-	468	-	468
Prepaid equity securities contracts	-	281,353	-	281,353
<b>Total financial assets measured at fair value</b>	<b>3,647</b>	<b>282,165</b>	<b>-</b>	<b>285,812</b>
Trading financial liabilities	14,302	1,750	-	16,052
Issued warrants	-	281,353	-	281,353
Issued structured notes	-	467	-	467
<b>Total financial liabilities measured at fair value</b>	<b>14,302</b>	<b>283,570</b>	<b>-</b>	<b>297,872</b>

# MORGAN STANLEY ASIA PRODUCTS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

### 20. ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (CONTINUED)

#### a. Financial assets and liabilities recognised at fair value on a recurring basis (Continued)

The Company's valuation approach and fair value hierarchy categorisation for all classes of financial instruments recognised at fair value on a recurring basis is as follows:

Asset and Liability / Valuation Technique	Valuation Hierarchy Classification
<b>Derivatives</b>	
<b>Listed Derivative Contracts</b>	
<ul style="list-style-type: none"> <li>Listed derivatives that are actively traded are valued based on quoted prices from the exchange.</li> <li>Listed derivatives that are not actively traded are valued using the same techniques as those applied to OTC derivative contracts.</li> </ul>	<ul style="list-style-type: none"> <li>Level 1 - listed derivatives that are actively traded</li> <li>Level 2 - listed derivatives that are not actively traded</li> </ul>
<b>OTC Derivative Contracts</b>	
<ul style="list-style-type: none"> <li>OTC derivative contracts include option contracts related to equity prices.</li> <li>Depending on the product and the terms of the transaction, the fair value of OTC derivative products can be modeled using a series of techniques, including closed-form analytic formulas, such as the Black-Scholes option-pricing model, simulation models or a combination thereof. Many pricing models do not entail material subjectivity as the methodologies employed do not necessitate significant judgement, since model inputs may be observed from actively quoted markets, as is the case for option contracts. In the case of more established derivative products, the pricing models used by the Company are widely accepted by the financial services industry.</li> </ul>	<ul style="list-style-type: none"> <li>Generally Level 2 - OTC derivative products valued using observable inputs, or where the unobservable input is not deemed significant</li> </ul>
<b>Prepaid equity securities contracts, issued warrants and issued structured notes</b>	
<ul style="list-style-type: none"> <li>The Company issues warrants, structured notes and trades prepaid equity securities contracts that have coupon or repayment terms linked to the performance of equity securities, indices or currencies.</li> <li>Fair value of warrants, structured notes and prepaid equity securities contracts is determined using valuation models for the derivative and debt portions of the notes and traded prepaid equity securities contracts. These models incorporate inputs referencing identical or comparable securities, including prices to which the notes are linked, interest rate yield curves, option volatility and currency rates, and equity prices.</li> <li>Independent, external and traded prices for the notes are considered as well as the impact of the Company's own credit spreads which are based on secondary bond market spreads.</li> </ul>	<ul style="list-style-type: none"> <li>Generally Level 2</li> </ul>
<b>Loans</b>	
<ul style="list-style-type: none"> <li>The fair value of loans to other Morgan Stanley Group undertakings is estimated based on the present value of expected future cash flows using its best estimate of interest rate yield curves.</li> </ul>	<ul style="list-style-type: none"> <li>Generally Level 2</li> </ul>

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 20. ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (CONTINUED)

##### b. Transfers between Level 1 and Level 2 of the fair value hierarchy for financial assets and liabilities recognised at fair value on a recurring basis.

During the year, the Company reclassified approximately US\$161,000 (31 December 2019: US\$nil) of trading financial liabilities from Level 1 to Level 2. The reclassifications were due to a reduction in the volume of recently executed transactions and market price quotations for the listed equity derivatives.

##### c. Changes in Level 3 financial assets and liabilities recognised at fair value on a recurring basis

The following table present the changes in the fair value of the Company's Level 3 financial assets and financial liabilities for the year ended 31 December 2019. Level 3 instruments may be hedged with instruments classified in Level 1 and Level 2. The realised and unrealised gains/ (losses) for assets and liabilities within the Level 3 category presented in the following tables do not reflect the related realised and unrealised gains/(losses) on hedging instruments that have been classified by the Company within the Level 1 and/ or Level 2 categories.

The unrealised gains/(losses) during the year for assets and liabilities within the Level 3 category presented in the following tables herein may include changes in fair value during the period that were attributable to both observable and unobservable inputs.

The Morgan Stanley Group operates a number of intra-group policies to ensure that, where possible, revenues and related costs are matched. Where the trading positions included in the below tables are risk managed using financial instruments held by other Morgan Stanley Group undertakings, these policies potentially result in the recognition of offsetting gains or losses in the Company.

There were no transfers between Level 2 and Level 3 of the fair value hierarchy during current and prior year.

2019	Balance at 1 January 2019 US\$'000	Total gains or (losses) recognised in statement of comprehensive income <sup>(1)</sup> US\$'000	Purchases US\$'000	Sales US\$'000	Settlements US\$'000	Net transfers in and / or out of Level 3 US\$'000	Balance at 31 December 2019 US\$'000	Unrealised gains or (losses) for Level 3 assets / liabilities outstanding as at 31 December 2019
								US\$'000
Prepaid equity securities contracts	27,934	862	-	(28,796)	-	-	-	-
<b>Total financial assets measured at fair value</b>	27,934	862	-	(28,796)	-	-	-	-
Issued warrants	(27,934)	(862)	-	-	28,796	-	-	-
<b>Total financial liabilities measured at fair value</b>	(27,934)	(862)	-	-	28,796	-	-	-

<sup>(1)</sup> The total gains or (losses) are recognised in the statement of comprehensive income as detailed in the financial instruments accounting policy (note 3(c)).

## **MORGAN STANLEY ASIA PRODUCTS LIMITED**

### **NOTES TO THE FINANCIAL STATEMENTS**

**Year ended 31 December 2020**

#### **20. ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (CONTINUED)**

##### **d. Assets and liabilities measured at fair value on a non-recurring basis**

Non-recurring fair value measurements of assets or liabilities are those which are required or permitted in the statement of financial position in particular circumstances. There were no assets or liabilities measured at fair value on a non-recurring basis during the current or prior year.

#### **21. ASSETS AND LIABILITIES NOT MEASURED AT FAIR VALUE**

For all financial instruments not measured at fair value, the carrying amount is considered to be a reasonable approximation of fair value.

#### **22. CAPITAL MANAGEMENT**

The Morgan Stanley Group manages its capital on a global basis with consideration for its legal entities. The capital managed by the Morgan Stanley Group broadly includes ordinary share capital, preference share capital, subordinated loans and reserves.

The Morgan Stanley Group actively manages its consolidated capital position based upon, among other things, business opportunities, risks, capital availability and rates of return together with internal capital policies, regulatory requirements and rating agency guidelines. In the future the Morgan Stanley Group may expand or contract its capital base to address the changing needs of its businesses.

The Morgan Stanley Group also aims to adequately capitalise at a legal entity level whilst safeguarding that entity's ability to continue as a going concern and ensuring that it meets all regulatory capital requirements, so that it can continue to provide returns for the Morgan Stanley Group.

In order to maintain or adjust the capital structure as described above, the Company may issue new shares or sell assets to reduce debt. The Company manages its ordinary share capital of US\$50,000 (2019: US\$50,000) as capital.

The issuance of securities is part of the Company's operating activities. The Company has contractual obligations to deliver cash or underlying financial instruments to holders of the issued securities. Also, these obligations will not be settled in the Company's own equity instruments. These liabilities are not subordinated and the security holders rank equally with other creditors of the Company. The issued securities are also not contracts that evidence any residual interest in the assets of the Company. The Company therefore does not regard the financial liabilities derived from its issuance activity as part of its capital.

The Company has also entered into financial support agreement with its immediate parent, MSASP and with MSHK 1238, whereby MSASP and MSHK 1238 agree to provide financial support by way of funds injection in the form of equity capital or shareholder's loan in the event the Company needs funding to fulfil its obligations and liabilities under its issuance program.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 23. RELATED PARTY DISCLOSURES

##### Parent and subsidiary relationships

###### *Parent and ultimate controlling entity*

The Company's immediate parent undertaking is MSASP, which is registered in Cayman Islands.

The ultimate parent undertaking and controlling entity and the largest group of which the Company is a member and for which group financial statements are prepared is Morgan Stanley. Morgan Stanley is incorporated in the State of Delaware, the United States of America. Copies of its financial statements can be obtained from [www.morganstanley.com/investorrelations](http://www.morganstanley.com/investorrelations).

##### Key management compensation

Key management personnel are defined as those persons having authority and responsibility for planning, directing and controlling the activities of the Company. Key management personnel include the Board of Directors of the Company.

Due to the nature of the Company's activities, key management personnel provide minimal services specific to the Company and as a result, no compensation is paid to key management personnel in respect of their services to the Company.

##### Transactions with related parties

The Morgan Stanley Group conducts business for clients globally through a combination of both functional and legal entity organisational structures. Accordingly, the Company is closely integrated with the operations of the Morgan Stanley Group and enters into transactions with other Morgan Stanley Group undertakings on an arm's length basis for the purposes of utilising financing, trading and risk management, and infrastructure services. The nature of these relationships along with information about the transactions and outstanding balances is given below. All the amounts outstanding as disclosed below are unsecured and will be settled in cash via intercompany mechanism. The Company has not recognised any expense and has made no provision for impairment relating to the amount of outstanding balances from related parties (2019: US\$nil).

All operating expenses, including audit fees, are either borne by or recharged to other Morgan Stanley Group undertakings.

All issuances of financial liabilities are guaranteed by Morgan Stanley.

###### *Funding*

The Company receives general funding from and provides general funding to other Morgan Stanley Group undertakings.

###### *General Funding*

General funding is undated, unsecured, floating rate lending, other than certain funding which is dated on a rolling 395 day term. Funding may be received or provided for specific transaction related funding requirements, or for general operational purposes. The interest rates are established by the Morgan Stanley Group Treasury function for all entities within the Morgan Stanley Group and approximate the market rate of interest that the Morgan Stanley Group incurs in funding its business.



## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 23. RELATED PARTY DISCLOSURES (CONTINUED)

##### Transactions with related parties (continued)

###### General Funding (continued)

Details of the outstanding balances on these funding arrangements and the related interest income recognised in the statement of comprehensive income during the year are shown in the table below:

	2020		2019	
	Interest \$'000	Balance \$'000	Interest \$'000	Balance \$'000
<b>Rolling 395 day term</b>				
Amounts due from:				
The Company's direct parent undertaking	565	45,168	122	10,052
<b>Undated</b>				
Amounts due from:				
The Company's direct parent undertaking	4	1,085	-	722
Amounts due to:				
Other Morgan Stanley Group undertakings	-	49	-	47

###### Trading and risk management

The Company issues listed derivative contracts, warrants and structured notes and hedges the obligations arising from the issuance by entering into prepaid equity securities contracts, OTC derivative contracts and loans designated at FVPL with other Morgan Stanley Group undertakings. All such transactions are entered into on an arm's length basis. These transactions may give rise to credit risk either for the Company, or to a related party towards the Company.

The total amounts receivable and payable on issued warrants, issued structured notes, prepaid equity securities contracts, OTC derivative contracts and loans designated at FVPL outstanding at the year-end were as follows:

	2020	2019
	US\$'000	US\$'000
Amounts due from:		
The Company's direct parent undertaking	-	281,353
Other Morgan Stanley Group undertakings <sup>(1)</sup>	11,320	930
	<u>11,320</u>	<u>282,283</u>
Amounts due to:		
The Company's direct parent undertaking	-	153,886
Other Morgan Stanley Group undertakings	7,617	523
	<u>7,617</u>	<u>154,409</u>

<sup>(1)</sup> Amounts due from other Morgan Stanley Group undertakings include cash collateral of US\$6,508,000 (2019: \$118,000) pledged by the Company to MSIP to mitigate risk on exposures arising under OTC derivative contracts between the Company and MSIP.

## MORGAN STANLEY ASIA PRODUCTS LIMITED

### NOTES TO THE FINANCIAL STATEMENTS

Year ended 31 December 2020

#### 23. RELATED PARTY DISCLOSURES (CONTINUED)

##### Transactions with related parties (continued)

###### *Fees and commissions*

The Company incurs fee in respect of services performed by other Morgan Stanley Group undertaking. Fees incurred during the year are as follows:

	2020 US\$'000	2019 US\$'000
Fees paid to other Morgan Stanley Group undertaking	2,358	-

###### *Other related party transactions*

The Morgan Stanley Group operates a number of intra-group policies to ensure that, where possible, revenues and related costs are matched. The Company receives management charges by recharging certain expenses, including fees paid to the stock exchange and other Morgan Stanley Group undertakings, to the Company's direct parent undertaking. For the year ended 31 December 2020, a management charge of US\$10,297,000 (2019: US\$nil) is recognised in the statements of comprehensive income arising from such policies. An outstanding receivable relating to the management charge at reporting date is included within the general funding balances disclosed above.

## **PARTIES**

### **Issuer**

Morgan Stanley Asia Products Limited  
c/o Maples Corporate Services Limited  
PO Box 309  
Ugland House  
Grand Cayman  
KY1-1104  
Cayman Islands

### **Guarantor**

Morgan Stanley  
  
*Registered Office*  
The Corporation Trust Company  
Corporation Trust Center  
1209 Orange Street  
Wilmington  
DE 19801  
United States of America  
  
*Principal Executive Office*  
1585 Broadway  
New York  
NY 10036  
United States of America

### **Manager**

Morgan Stanley Asia Limited  
Level 46  
International Commerce Centre  
1 Austin Road West, Kowloon  
Hong Kong

### **Liquidity Provider**

Morgan Stanley Hong Kong Securities Limited  
Level 46  
International Commerce Centre  
1 Austin Road West, Kowloon  
Hong Kong

### **Legal Advisers**

*to the Issuer and the Guarantor*

King & Wood Mallesons  
13/F, Gloucester Tower  
The Landmark  
15 Queen's Road Central  
Hong Kong

### **Issuer's and Guarantor's Auditor**

Deloitte & Touche LLP  
30 Rockefeller Plaza  
New York  
New York 10112  
United States of America

